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A B S T R A C T
Background
The treatment of multiple sclerosis has changed over the last 20 years. The advent of disease-modifying drugs in themid-1990s heralded
a period of rapid progress in the understanding and management of multiple sclerosis. With the support of magnetic resonance imaging
early diagnosis is possible, enabling treatment initiation at the time of the first clinical attack. As most of the disease-modifying drugs
are associated with adverse events, patients and clinicians need to weigh the benefit and safety of the various early treatment options
before taking informed decisions.
Objectives
1. to estimate the benefit and safety of disease-modifying drugs that have been evaluated in all studies (randomised or non-randomised)
for the treatment of a first clinical attack suggestive of MS compared either with placebo or no treatment;
2. to assess the relative efficacy and safety of disease-modifying drugs according to their benefit and safety;
3. to estimate the benefit and safety of disease-modifying drugs that have been evaluated in all studies (randomised or non-randomised)
for treatment started after a first attack (’early treatment’) compared with treatment started after a second attack or at another later time
point (’delayed treatment’).
Search methods
We searched the Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group Trials Register, MEDLINE, Embase, CINAHL,
LILACS, clinicaltrials.gov, theWHO trials registry, andUS Food andDrugAdministration (FDA) reports, and searched for unpublished
studies (until December 2016).
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Selection criteria
We included randomised and observational studies that evaluated one or more drugs as monotherapy in adult participants with
a first clinical attack suggestive of MS. We considered evidence on alemtuzumab, azathioprine, cladribine, daclizumab, dimethyl
fumarate, fingolimod, glatiramer acetate, immunoglobulins, interferon beta-1b, interferon beta-1a (Rebif®, Avonex®), laquinimod,
mitoxantrone, natalizumab, ocrelizumab, pegylated interferon beta-1a, rituximab and teriflunomide.
Data collection and analysis
Two teams of three authors each independently selected studies and extracted data. The primary outcomes were disability-worsening,
relapses, occurrence of at least one serious adverse event (AE) and withdrawing from the study or discontinuing the drug because of AEs.
Time to conversion to clinically definite MS (CDMS) defined by Poser diagnostic criteria, and probability to discontinue the treatment
or dropout for any reason were recorded as secondary outcomes. We synthesized study data using random-effects meta-analyses and
performed indirect comparisons between drugs. We calculated odds ratios (OR) and hazard ratios (HR) along with relative 95%
confidence intervals (CI) for all outcomes. We estimated the absolute effects only for primary outcomes. We evaluated the credibility
of the evidence using the GRADE system.
Main results
We included 10 randomised trials, eight open-label extension studies (OLEs) and four cohort studies published between 2010 and
2016. The overall risk of bias was high and the reporting of AEs was scarce. The quality of the evidence associated with the results
ranges from low to very low.
Early treatment versus placebo during the first 24 months’ follow-up
There was a small, non-significant advantage of early treatment compared with placebo in disability-worsening (6.4% fewer (13.9 fewer
to 3 more) participants with disability-worsening with interferon beta-1a (Rebif®) or teriflunomide) and in relapses (10% fewer (20.3
fewer to 2.8 more) participants with relapses with teriflunomide). Early treatment was associated with 1.6% fewer participants with
at least one serious AE (3 fewer to 0.2 more). Participants on early treatment were on average 4.6% times (0.3 fewer to 15.4 more)
more likely to withdraw from the study due to AEs. This result was mostly driven by studies on interferon beta 1-b, glatiramer acetate
and cladribine that were associated with significantly more withdrawals for AEs. Early treatment decreased the hazard of conversion to
CDMS (HR 0.53, 95% CI 0.47 to 0.60).
Comparing active interventions during the first 24 months’ follow-up
Indirect comparison of interferon beta-1a (Rebif®) with teriflunomide did not show any difference on reducing disability-worsening
(OR 0.84, 95% CI 0.43 to 1.66). We found no differences between the included drugs with respect to the hazard of conversion to
CDMS. Interferon beta-1a (Rebif®) and teriflunomide were associated with fewer dropouts because of AEs compared with interferon
beta-1b, cladribine and glatiramer acetate (ORs range between 0.03 and 0.29, with substantial uncertainty).
Early versus delayed treatment
We did not find evidence of differences between early and delayed treatments for disability-worsening at a maximum of five years’
follow-up (3% fewer participants with early treatment (15 fewer to 11.1 more)). There was important variability across interventions;
early treatment with interferon beta-1b considerably reduced the odds of participants with disability-worsening during three and five
years’ follow-up (OR 0.52, 95% CI 0.32 to 0.84 and OR 0.57, 95% CI 0.36 to 0.89). The early treatment group had 19.6% fewer
participants with relapses (26.7 fewer to 12.7 fewer) compared to late treatment at a maximum of five years’ follow-up and early
treatment decreased the hazard of conversion to CDMS at any follow-up up to 10 years (i.e. over five years’ follow-up HR 0.62, 95%
CI 0.53 to 0.73). We did not draw any conclusions on long-term serious AEs or discontinuation due to AEs because of inadequacies
in the available data both in the included OLEs and cohort studies.
Authors’ conclusions
Very low-quality evidence suggests a small and uncertain benefit with early treatment compared with placebo in reducing disability-
worsening and relapses. The advantage of early treatment compared with delayed on disability-worsening was heterogeneous depending
on the actual drug used and based on very low-quality evidence. Low-quality evidence suggests that the chances of relapse are less with
early treatment compared with delayed. Early treatment reduced the hazard of conversion to CDMS compared either with placebo, no
treatment or delayed treatment, both in short- and long-term follow-up. Low-quality evidence suggests that early treatment is associated
with fewer participants with at least one serious AE compared with placebo. Very low-quality evidence suggests that, compared with
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placebo, early treatment leads to more withdrawals or treatment discontinuation due to AEs. Difference between drugs on short-term
benefit and safety was uncertain because few studies and only indirect comparisons were available. Long-term safety of early treatment
is uncertain because of inadequately reported or unavailable data.
P L A I N L A N G U A G E S U M M A R Y
Disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis
This summary presents data about the benefit and side effects of some disease-modifying drugs used at the time when multiple sclerosis
is diagnosed after a first clinical attack. We reviewed the available evidence to answer three questions: 1) is early treatment beneficial
and safe? 2) which drug is best for early treatment? 3) is early treatment better than later treatment?
Sufficient data were available from 22 studies on the following drugs: cladribine (Movectro), glatiramer acetate (Copaxone), interferon
beta-1b (Betaferon), interferon beta-1a (Rebif; Avonex), and teriflunomide (Aubagio).
First question: is early treatment beneficial and safe?
Disability-worsening
Among people who took Aubagio or Rebif, 28 people out of 100 experienced disability-worsening over two years’ treatment compared
to 34 people out of 100 who took placebo (6% absolute benefit). The overall quality of the included studies is very low, so our confidence
in this result is low.
Relapse
Early treatment was associated with lower proportions of people who had a second attack - ie who received a diagnosis of MS - during the
first two years’ treatment, compared to people who took placebo. Among people who took Aubagio, 32 people out of 100 experienced
recurrent relapses over two years’ treatment compared to 42 people out of 100 who took placebo (10% absolute benefit). Again, the
overall quality of evidence is very low.
Serious side effects
Among people who took Aubagio, Avonex, Betaferon, Copaxone, Movectro, or Rebif, there is probably little or no difference in serious
side effects over two years’ treatment compared with people who took placebo.
Side effects
Among people who took Betaferon, 11 people out of 100 experienced side effects compared to one person out of 100 people who took
placebo (10% absolute harm). Among people who took Movectro, seven people out of 100 experienced side effects compared to two
out of 100 people who took placebo (5% absolute harm). Among people who took Copaxone, six people out of 100 experienced a side
effect compared to two out of 100 people who took placebo (4% absolute harm).
Second question: which drug is best for early treatment?
Disability-worsening
Indirect comparison of Rebif with Aubagio did not show any difference on reducing disability-worsening over two years’ treatment.
However, there were few studies and the overall quality of evidence is very low.
Relapse
Only one study on Aubagio was available, so we cannot compare the effects of each drug compared with one other.
Side effects
Rebif and Aubagio were associated with fewer dropouts because of side effects compared with Betaferon, Copaxone, or Movectro.
Third question: is early treatment better than later treatment?
Disability-worsening
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Among people who received early treatment with Avonex, Betaferon, Copaxone, or Rebif, 37 people out of 100 experienced disability-
worsening at a maximum of five years’ follow-up compared with 40 people out of 100 who received later treatment (3% absolute
benefit). However, the great variability between the studies and the low quality of the evidence make our confidence in this result low.
Relapse
Early treatment was associated with lower proportions of people who had a second attack at any follow-up up to 10 years, compared
to people who received later treatment. Among people who received early treatment with Betaferon, Copaxone, or Rebif, 64 people
out of 100 experienced recurrent relapses at a maximum of five years’ follow-up compared to 83 people out of 100 who received these
drugs later (19% absolute benefit).
Side Effects
Wedidnot draw any conclusions on long-term serious side effects or treatment discontinuationdue to side effects because of inadequacies
in the available data in the included studies.
Conclusion
The low-quality evidence of the included studies suggests a small and uncertain benefit with early treatment compared with placebo or
later treatment in reducing disability-worsening and relapses.
We cannot draw conclusions on the long-term safety of these drugs when administered as early treatment because of inadequately
reported or unavailable data.
Until convincing evidence of any difference on benefit between disease-modifying drugs becomes available, the drugs that have been
in use in clinical practice for many years and whose safety profile is better understood are probably the most sensible choice for early
treatment.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Patient: adults with f irst attack suggest ive of MS
Setting: MS centres
Intervention: early disease-modif ying drug treatment
Comparison: placebo
Outcomes Relative effect
(95% CI)
Anticipated absolute effects∗ (95% CI) Quality of the evi-
dence
(GRADE)
What happens
With placebo With early disease-
modifying drugs
treatment
Difference
Disability-
worsening
Proport ion of part ic-
ipants with disabil-
ity-worsening, as-
sessed by EDSS* *
during 24 months of
treatment
Part icipants: N =
927
(2 RCTs)
OR 0.74
(0.49 to 1.14)
34.1% 27.7%
(20.2 to 37.1)
6.4% fewer (13.9
fewer to 3 more)
⊕©©©
Very lowa,b,c
The risk of disabil-
ity-worsening is less
with disease-modi-
f ying drugs than
with placebo, but
there is a lot of un-
certainty in the ef -
fect
Relapse
Proport ion of part ic-
ipants with relapse
during 24 months of
treatment
Part icipants: N =
618
(1 RCT)
OR 0.65
(0.38 to 1.12)
41.6% 31.7%
(21.3 to 44.4)
10.0% fewer (20.3
fewer to 2.8 more)
⊕©©©
Very lowa,c,d
The risk of relapse
is less with disease-
modif y-
ing drugs than with
placebo, but there is
a lot of uncertainty
in the ef fects
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Occurrence of at
least one serious
adverse event Pro-
port ion of part ici-
pants with at least
one serious adverse
event during 24
months of treatment
Part icipants: N =
3385
(7 RCTs)
OR 0.78
(0.60 to 1.03)
8.0% 6.3%
(5.0 to 8.2)
1.6% fewer
(3 fewer to 0.2 more)
⊕⊕©©
Lowa,e
Compared
to placebo, disease-
modif y-
ing drugs were asso-
ciated with less risk
of serious adverse
events
Withdrawls or drug
discontinuation due
to adverse events
during 24 months of
treatment
Part icipants: N =
2693
(5 RCTs)
OR 2.43
(0.91 to 6.49)
3.5% 8.0%
(3.2 to 18.9)
4.6% more
(0.3 fewer to 15.4
more)
⊕©©©
Very lowa,f,g
Compared to
placebo interferon
beta 1-b, glat iramer
acetate, and cladrib-
ine were associated
with higher risk of
withdrawals due to
adverse events
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of
the intervent ion (and its 95% CI).
* * EDSS: expanded disability status scale
CI: Conf idence interval; OR: Odds rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a
possibility that it is substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aHigh risk of bias for blinding of part icipants and outcome assessment and incomplete outcome data.
bSurrogate outcome in both studies contribut ing to this est imate.
cThe conf idence interval does not rule out a null ef fect or benef it .
dOnly one study contributed to this est imate.
6
T
re
a
tm
e
n
t
w
ith
d
ise
a
se
-m
o
d
ify
in
g
d
ru
g
s
fo
r
p
e
o
p
le
w
ith
a
fi
rst
c
lin
ic
a
l
a
tta
c
k
su
g
g
e
stiv
e
o
f
m
u
ltip
le
sc
le
ro
sis
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
7
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
eDef init ion and methods of monitoring and detect ing serious adverse events not reported in most trials.
f High heterogeneity (I² = 78%, P = 0.001) not explained; high subgroup dif ferences (I² = 75%, P = 0.003).
gDef init ion and methods of monitoring and detect ing adverse events not reported in most trials.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Description of the condition
Since the revision of the McDonald criteria in 2010 (Polman
2011), multiple sclerosis (MS) can be diagnosed at the time of
a first clinical attack when magnetic resonance imaging (MRI)
shows the presence of focal lesions in the white matter of the cen-
tral nervous system, which are considered typical for MS in terms
of distribution, morphology, evolution and signal abnormalities
on conventional MRI sequences (Filippi 2016). Opinion leaders
have recommended early action as “treating at first clinical at-
tack may be the most effective strategy to manage disease progres-
sion” (Freedman 2014). Revised guidelines of the Association of
British Neurologists (Scolding 2015) and NHS England (NHS
England 2014) suggest that treatment should be advised for pa-
tients within 12 months of a first attack, if MRI establishes a diag-
nosis of MS according to the 2010 McDonald criteria or predicts
a high likelihood of recurrent attacks. The benefit of starting early
treatment with disease-modifying drugs has been demonstrated
by some short-term trials that showed delay of a second attack in
participants given interferons beta (ETOMS 2001) or glatiramer
acetate (PRECISE 2009) compared with those on placebo. On
the basis of these results, interferons beta and glatiramer acetate
were approved by national regulatory agencies for treating MS at
clinical onset (EMA 2015a). However, the available evidence does
not indicate that the prevention of recurrent attacks has an ef-
fect on disability (CHAMPS 2012 (10 years FU); Frischer 2009),
and large variability of long-term disability-worsening has been
reported, even among people with frequent early relapses (Scalfari
2013).
Once the decision for early treatment is made, patients and their
healthcare providers need to select one of several disease-modi-
fying drugs. Most of the evidence about the relative efficacy and
safety of interventions is non-specific to early treatment. In a pre-
viously published review, moderate- to high-quality evidence sug-
gested that alemtuzumab, natalizumab and fingolimod were asso-
ciated with greater benefit for preventing recurrent attacks com-
pared with placebo, and evidence of moderate quality indicated
that natalizumab was associated with greater benefit for preventing
disability-worsening among all treatments evaluated (Tramacere
2015).Despite alemtuzumab andnatalizumabhavingbeenproven
to exert higher relapse suppression, because of safety concerns, the
guidelines of theAssociation of BritishNeurologists recommended
their use as second-line treatment, or as treatment for people with
rapidly evolving relapsing-remitting MS. Beta interferons, glati-
ramer acetate, teriflunomide, dimethyl fumarate and fingolimod
are recommended as first-line agents (Scolding 2015). Australian
and New Zealand guidelines allow neurologists the discretionary
use of all disease-modifying drugs as first-line treatments (Broadley
2014).
Description of the intervention
We considered all disease-modifying drugs that are used, approved
or off-label, or are currently under marketing authorisation or
investigation for people with a first clinical attack. We considered
that all agents used or under investigation for relapsing-remitting
MS could be given to people with a first attack complying with
the 2010 McDonald criteria. More specifically, we are interested
in drugs that have been approved for a first attack complying with
2010 McDonald criteria.
• Beta interferons (Betaferon/Betaseron®; Extavia®; Rebif®;
Avonex®) and glatiramer acetate (Copaxone®) (EMA 2015a;
FDA 2012a; FDA 2012b; FDA 2013). These medications are
administered subcutaneously, except for beta interferon 1a
(Avonex®), which is administered via intramuscular injections.
Approved for relapsing-remitting MS
• Natalizumab (Tysabri®) (EMA 2006; FDA 2006)
administered by intravenous infusion at a dose of 300 mg every
four weeks
• Fingolimod (Gilenya®) (EMA 2011; FDA 2010) given at
an oral dose of 0.5 mg once daily
• Teriflunomide (Aubagio®) (EMA 2013a; FDA 2012) given
at an oral dose of 7 mg or 14 mg once daily
• Dimethyl fumarate (Tecfidera®) (EMA 2014a; FDA 2013)
given at an oral dose of 240 mg twice daily
• Alemtuzumab (Lemtrada®) (EMA 2013b; FDA 2014a)
administered intravenously in two annual treatment courses - the
first at a dose of 12 mg daily on five consecutive days (60 mg
total dose), and the second, 12 months later, on three
consecutive days (36 mg total dose)
• Daclizumab (Zinbryta®) administered by subcutaneous or
intravenous injections and approved by the European Medicines
Agency (EMA) (EMA 2016) and the Food and Drug
Administration (FDA) (FDA 2016)
• Ocrelizumab (Ocrevus®) (FDA 2017) administered
intravenously at an initial single dose of 300 mg followed two
weeks later by a second 300 mg intravenous infusion.
Subsequent doses of 600 mg intravenously every six months.
Approved for relapsing forms of MS and primary progressive MS
• Pegylated interferon beta-1a (Plegridy®) (EMA 2014b;
FDA 2014b) given by subcutaneous injection at a dose of 125 µg
every 14 days
• Cladribine (Movectro®) approved in Russia and Australia
in 2010 (Murphy 2010). EMA (EMA 2015b) and FDA in 2011
did not approve it because of a suspected increase in cancer risk.
A meta-analysis failed to confirm these concerns (Pakpoor 2015)
• Mitoxantrone (Novantrone®) approved in 2000 in the
USA (FDA 2000), Europe and other countries for relapsing-
remitting and progressive MS. It is administered as a short
intravenous infusion every three months. Safety concerns include
cardiotoxicity and acute leukaemia
• Azathioprine (Imuran®) used in many countries on the
basis of placebo-controlled randomised controlled trials (RCTs)
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published more than two decades ago. However, since interferons
beta were approved, azathioprine is no longer recommended as
first-line therapy (Goodin 2002). It is taken orally, 2 mg/kg or 3
mg/kg per day. Intravenous immunoglobulins are used for
people with severe and frequent relapses, for whom other
treatments were contraindicated (Scolding 2015)
• Rituximab (Rituxan® or Mabthera®) administered
intravenously. Currently under marketing authorisation or
investigation
• Laquinimod (Nerventra®) given at an oral dose of 0.6 mg
daily. The drug received a negative opinion from EMA (EMA
2014c). Studies of laquinimod in relapsing-remitting MS are
ongoing (Active Biotech 2014).
How the intervention might work
Immunosuppressive or immunomodulatory effects are common
to all treatments included in the review.
• Approved interventions
◦ Beta interferons are naturally occurring cytokines that
possess antiviral activity and a wide range of anti-inflammatory
properties. Recombinant beta interferons are believed to directly
increase expression and concentration of anti-inflammatory
agents, while downregulating expression of pro-inflammatory
cytokines (Kieseier 2011).
◦ Glatiramer acetate exerts an immunomodulatory
action by inducing tolerance or anergy of myelin-reactive
lymphocytes (Schmied 2003). Glatiramer acetate may promote
neuroprotective repair processes (Aharoni 2014).
◦ Natalizumab is a humanised monoclonal antibody
directed against the alfa4 integrin. This integrin is essential in the
process by which lymphocytes gain access to the brain by
allowing cells to penetrate the blood-brain barrier. Natalizumab
binds alfa4β1 and alfa4β7 integrin on the surface of circulating
T lymphocytes, preventing interaction with cellular adhesion
molecules that facilitate extravasation and migration from the
circulation to the central nervous system (CNS) (Millard 2011).
◦ Fingolimod is a sphingosine-1-phosphate (S1P)
receptor modulator that prevents lymphocyte egress from
lymphoid tissues, thereby reducing autoaggressive lymphocyte
infiltration into the CNS. S1P receptors are also expressed by
many CNS cell types and have been shown to influence cell
proliferation, morphology and migration. Fingolimod crosses the
blood-brain barrier and therefore may have direct CNS effects
(Chun 2010).
◦ Teriflunomide acts as an inhibitor of dihydroorotate
dehydrogenase (DHODH), a mitochondrial enzyme involved in
pyrimidine synthesis for DNA replication in rapidly proliferating
cells. The drug reduces T lymphocyte and B lymphocyte
activation and proliferation, and may attenuate the
inflammatory response to autoantigens in MS. However, the
exact mechanism of action for teriflunomide is not fully
understood. Some observations suggest that the drug may have
immunological effects outside of its ability to inhibit pyrimidine
synthesis in rapidly proliferating cells (Claussen 2012; Oh 2013).
◦ Dimethyl fumarate derives from fumaric acid,
promotes anti-inflammatory activity and can inhibit expression
of pro-inflammatory cytokines and adhesion molecules. Actions
of neuroprotective and myelin-protective mechanisms have been
proposed (Linker 2011; Wilms 2010).
◦ Alemtuzumab is a monoclonal antibody to CD52 on
the cell surface of lymphocytes and monocytes. Its effects are
thought to be mediated by extended B and T lymphocyte
depletion followed by a distinctive pattern of T and B cell
repopulation that begins within weeks of treatment and leads to
a rebalanced immune system, including an increased percentage
of regulatory and memory T cells. Effects of alemtuzumab
persisted after it was cleared from the circulation (Lycke 2015).
◦ Daclizumab is a monoclonal antibody to the
interleukin-2 receptor CD25 that is expressed on immune cells.
The exact mechanism is not well understood. Daclizumab
interrupts interleukin-2-mediated cell activation, thereby
preventing expansion of autoreactive T lymphocytes and
inhibiting survival of activated T cells (Wuest 2011).
◦ Ocrelizumab is a recombinant monoclonal antibody
designed to selectively target CD20-positive B lymphocytes, a
specific type of immune cell thought to be a key contributor to
myelin and axonal nerve cell damage. The drug depletes CD20
B cells, it increases antibody-dependent cell-mediated
cytotoxicity effects and reduces complement-dependent
cytotoxicity effects (Kappos 2011).
◦ Pegylated interferon beta-1a (PEG-IFN) is the drug
obtained by PEGylation of IFN beta-1a (Avonex®) (i.e. joining
of a polyethylene glycol group (PEG) molecule to the IFN beta-
1a molecule). PEGylation has been applied to increase IFN
stability, solubility and half-life, and to reduce dosing frequency
(Hu 2012).
◦ Cladribine is a chemotherapeutic drug approved for
treatment of people with hairy-cell leukaemia, a subtype of
chronic lymphoid leukaemia. Short courses of cladribine induce
prolonged lymphopenia by selectively interfering with DNA
synthesis and repair in T and B lymphocytes lasting months to
years (Leist 2011).
◦ Mitoxantrone is a cytotoxic drug that intercalates with
DNA and inhibits both DNA and RNA synthesis, thus reducing
the number of lymphocytes (Fox 2004).
• Interventions used off-label
◦ Azathioprine is a cytotoxic immunosuppressive drug
that acts as a prodrug for mercaptopurine, inhibiting an enzyme
required for DNA synthesis. Thus it most strongly affects
proliferating cells, such as T cells and B cells of the immune
system (Tiede 2003).
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◦ Intravenous immunoglobulins may improve
remyelination of demyelinated axons through mediation of
cytokines. However, their mechanism of action in MS remains
unclear (Stangel 1999).
◦ Rituximab is a monoclonal antibody to CD20
expressed on pre-B and mature B cells; it acts by depleting these
cells in the circulation and the CNS. Although MS was
traditionally considered a T cell-mediated disease, accumulating
evidence suggests that B cells may play a role (Lycke 2015;
Naismith 2010).
• Interventions currently under marketing authorisation or
investigation
◦ Laquinimod may have an immunomodulatory effect
on the peripheral and central nervous systems. This drug
modulates the function of various myeloid antigen-presenting
cell populations, which then downregulate pro-inflammatory T
cell responses. Furthermore, data indicate that laquinimod acts
directly on resident cells within the CNS to reduce
demyelination and axonal damage. However, exactly how the
drug works remains unknown (Varrin-Doyer 2014).
Why it is important to do this review
Uncertainty
Many treatment options are available, and patients and their clin-
icians may choose to start with a drug of moderate efficacy and
general safety or with a drug of high efficacy and a complex sa-
fety profile. Consequently, a comprehensive appreciation of the
benefits and risks of all treatment approaches is urgently needed
(Scolding 2015; Wingerchuk 2014).
Early treatment
Interferons and glatiramer acetate are indicated by the FDA and
the EMA for treatment of people who have experienced a first at-
tack and are at high risk of recurrent attacks. Other immunother-
apies have been reported to delay recurrent attacks, although their
effect on disability prevention remains unclear. In addition, vari-
ous national guidelines provide conflicting information about ef-
fects of these treatments and their use as first-line or second-line
therapy (see Description of the condition). This uncertainty re-
sults from several factors, including intermediate outcomes and
short follow-up periods in the clinical trials included in published
reviews. Immunotherapies administered early in the disease can
delay intermediate outcomes (i.e. short-term relapses), but sup-
pression of early relapses may not necessarily correlate with long-
term disability prevention (Frischer 2009; Scalfari 2013). There-
fore an effect on disability cannot be claimed solely on the basis of
relapse prevention (EMA 2015a). Given that most evidence has
been derived from short-term trials with low power to investigate
rare adverse events, safety outcomes have not been extensively in-
vestigated. Consequently, a demonstration and quantification of
the benefit and safety of the early treatment versus delayed treat-
ment is still required.
Choice of interventions for early treatment
Patients and their doctors must be given information about the
relative benefit and safety of the various treatment options if they
are to make informed decisions. Various disease-modifying drugs
have been shown to have different benefit/acceptability profiles.
Differences in benefit are as important to consider as differences
in safety. For example, local injection site reactions and flu-like
symptoms have emerged as the main adverse effects of interferons
beta, and cardiotoxicity and acute leukaemia as major safety issues
for mitoxantrone. Investigators have described fatal cases of pro-
gressive multi-focal leucoencephalopathy in people treated with
natalizumab (EMA 2006), fingolimod (EMA 2011) and dimethyl
fumarate (EMA 2014a). To support informed decision-making,
there is a need to identify, systematically collect and synthesise in-
formation about relative safety and efficacy between interventions
administered to people with the first attack suggestive of MS.
Relevance
In July 2014, Cochrane Multiple Sclerosis launched a ‘Priority
Setting Survey’ and invited consumers and MS societies to an-
swer a questionnaire identifying priority research questions con-
sidered to have the most relevant impact for all stakeholders. The
question - “Early onset of treatment may avoid disease progres-
sion?” - was one of the most frequently reported by people with
MS and family members. The question - “Does early treatment
with aggressive disease-modifying drugs improve the prognosis for
people with MS?” - addresses one of the top 10 MS priorities re-
ported by the James Lind Alliance in collaboration with the UK
MS Society 2012. This review aims to answer these two questions
by comparing all disease-modifying drugs with placebo; it also
plans to provide an assessment of the relative effects of each drug
compared with one other and a ranking of treatments according
to benefit and safety. The significance of this project is underlined
by the fact that evaluation of disease-modifying drugs for people
with a first clinical attack has been identified as a priority and is
featured in the Cochrane Priority Review List 2015/16.
Most published reviews have compared a single treatment versus
placebo and have made inferences about benefits and safety. This
information is unlikely to be useful in practice, as people with MS
have several treatment options. Network meta-analysis (NMA),
which is an extension of the traditional pairwise meta-analysis,
collates information from studies comparing different treatments
in order to form a ‘network of interventions’. This provides in-
formation about the relative effects of all interventions included
in the network, even those not directly compared in any trial and
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a hierarchy of treatments ordered by efficacy and safety. None of
the existing comparative effectiveness reviews have specifically ad-
dressed disease-modifying drugs in early treatment. As the num-
ber of people who choose to start treatment soon after diagnosis
increases, it is important for healthcare providers to know the rel-
ative benefit and safety of the various treatment options in this
particular setting.
Another important limitation of existing reviews is that all in-
clude randomised controlled trials. Although this study design is
theoretically associated with low risk of bias, it has several short-
comings. First, randomised trials do not provide patient follow-
up for a long period; consequently, this design is not appropri-
ate when rare safety outcomes are of interest. Second, randomised
trials are typically undertaken in highly selected conditions and
do not represent real-world settings. Consequently, the general-
isability of findings is doubtful. For these reasons, interest in in-
cluding non-randomised studies in the decision-making process
is growing (Faria 2015), and innovative methods have been devel-
oped for combining data obtained through different study designs
(Schmitz 2013; Verde 2015).
Overall, we believe that despite the wealth of information and the
plethora of studies and reviews on treatments for MS, uncertainty
surrounds the relative ranking of disease-modifying drugs when
treatment starts early. In particular, the issue of safety is less well
studied, as evidence from non-randomised studies that provide
useful information on adverse events has not been systematically
considered. We believe that having access to high-quality health
information is an essential component of good decision-making
processes and helps people take control of their health. Our cer-
tainty comes from the results of studies previously undertaken by
Cochrane Multiple Sclerosis, wherein people with MS and their
family members told us that they want access to high-quality in-
formation about MS provided by sources they can trust (Colombo
2014; Colombo 2016; Hill 2012; Synnot 2014).
Potential to change or influence clinical practice or
health policy
The review aimed toprovide critical informationnecessary inmak-
ing informed healthcare decisions on treatments for people with
MS, their neurologists and familymembers.Notably,marked vari-
ability in treatment decisions has been reported, likely as the result
of physician preference and opinion (Palace 2013). Disease-mod-
ifying drugs are expensive and their use has significant economic
implications for the healthcare system. These treatments are as-
sociated with high risk of adverse events, which indirectly further
increases treatment costs. Identifying treatment that offers a better
benefit and safety profile, with particular attention to safety, may
help to reduce costs.
O B J E C T I V E S
The review aimed to answer three research questions:
• is early treatment efficacious and safe compared to placebo
or no treatment?
• are there differences in efficacy and safety between the
various drugs administered for early treatment?
• is early treatment better than delayed treatment?
Consequently, the objectives were:
• to estimate the benefit and safety of disease-modifying
drugs that have been evaluated in all studies (randomised or non-
randomised) for the treatment of a first clinical attack suggestive
of MS compared either with placebo or no treatment;
• to assess the relative efficacy and safety of disease-modifying
drugs according to their benefit and safety;
• to estimate the benefit and safety of disease-modifying
drugs that have been evaluated in all studies (randomised or non-
randomised) for treatment started after a first attack (’early
treatment’) compared with treatment started after a second
attack or at another later time point (’delayed treatment’).
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included RCTs, open-label extension (OLE) studies, con-
trolled clinical trials, cohort studies and registries. Inclusion of
non-randomised controlled studies was supported by the aim to
provide additional evidence about long-term outcomes (in par-
ticular safety outcomes) and populations that are typical of real
world practice.
An OLE study follows on from a RCT. At the end of the RCT or
after the occurrence of a primary outcome event (e.g. conversion
to MS), participants receiving placebo were offered the option to
switch to the active treatment during an ‘open-label’ follow-up.
In these studies efficacy and safety were evaluated comparing the
early-treatment group with the delayed-treatment group.
We included studies with follow-up of at least one year. We ex-
cluded non-comparative studies.
Types of participants
Adults (aged 18 years or older) with a first clinical attack suggestive
of MS as defined in the original articles. We included participants
with optic neuritis, isolated brainstem or cerebellar syndrome or
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spinal cord or other clinical syndrome as a first attack and mono-
focal or multi-focal first attacks.
Types of interventions
The following interventions administered as monotherapy were
eligible for inclusion: alemtuzumab, azathioprine, cladribine,
daclizumab, dimethyl fumarate, fingolimod, glatiramer acetate,
immunoglobulins, interferon beta-1b (Betaseron®), subcuta-
neous interferon beta-1a (Rebif®), intramuscular interferon beta-
1a (Avonex®), laquinimod, mitoxantrone, natalizumab, ocre-
lizumab, pegylated interferon beta-1a, rituximab and terifluno-
mide.We included regimens irrespective of their dose and assumed
that treatments are ’jointly randomisable’ across trial participants
(Salanti 2012). To address the first two review questions we in-
cluded studies comparing disease-modifying drugs with placebo,
no treatment or another active treatment. To address the third
question we included studies comparing early treatment versus de-
layed treatment with disease-modifying drugs. We excluded com-
bination treatments, non-pharmacological treatments, and inter-
ventions consisting of over-the-counter drugs.
Types of outcome measures
Primary outcomes
Primary efficacy outcomes
Disability-worsening
We measured this as the proportion of participants who experi-
enced disability-worsening (as defined by the study authors) at 24
months, 36 months or at the end of the study. Most investigators
used the expanded disability status scale (EDSS) (Kurtzke 1983).
EDSS is based on the results of a neurological examination and
the patient’s ability to walk. Scores range from 0 (no neurologi-
cal abnormality) to 10 (death from multiple sclerosis). Disability-
worsening is often defined as a sustained (3 months or 6 months)
increase of at least one point in EDSS recorded over a relapse-free
period.
Relapses
We measured this as the proportion of participants who experi-
enced new relapses over 12 months, 24 months and 36 months or
at the end of the study. A relapse is defined as a newly developed
or recently worsened symptom of neurological dysfunction that
lasted more than 24 hours with or without objective confirmation
and that stabilised or resolved either partly or completely.
Primary safety outcomes
Occurrence of at least one serious adverse event
We measured this as the proportion of participants with at least
one serious adverse event during the study.
Withdrawing from the study or discontinuing the drug due
to adverse events
Wemeasured this as the proportion of participants who withdrew
from the study or discontinued the drug due to adverse events
during the study.
Secondary outcomes
Time to conversion to clinically definite multiple sclerosis
(CDMS)
As defined by Poser diagnostic criteria (Poser 1983).
Withdrawing from the study or discontinuing the drug for
any reason
We measured this as the proportion of participants who discon-
tinued treatment and were followed-up to the end of the study or
who were lost to follow-up for any reason.
Search methods for identification of studies
We did not apply any language restrictions to the search.
Electronic searches
The Information Specialist searched the Cochrane Multiple Scle-
rosis and Rare Diseases of the CNS Trials Register , which, among
other sources, contains trials from:
• Cochrane Central Register of Controlled Trials
(CENTRAL; 2016, issue 12);
• MEDLINE (PubMed) (1966 to 31 December 2016);
• Embase (Embase.com) (1974 to 31 December 2016);
• Cumulative Index to Nursing and Allied Health Literature
(CINAHL) (EBSCOhost) (1981 to 31 December 2016);
• Latin American and Caribbean Health Science Information
Database (LILACS) (Bireme) (1982 to 31 December 2016);
• ClinicalTrials.gov (www.clinicaltrials.gov); and
• World Health Organization (WHO) International Clinical
Trials Registry Platform (apps.who.int/trialsearch).
Information on the Trials Register or the ReviewGroup and details
of the search strategies used to identify trials can be found in
the ’Specialised Register’ section within the Cochrane Multiple
Sclerosis and Rare Diseases of the CNS module. We described
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in Appendix 1 the keywords that we used to search for trials.
We performed an expanded search to identify articles of non-
randomised studies in MEDLINE (Appendix 2) and Embase (
Appendix 3).
Searching other resources
• We handsearched the reference lists of all retrieved articles,
texts and other reviews on the topic.
• We contacted study authors and researchers active in this
field to ask for additional data, if necessary.
• We searched for FDA and EMA reports.
Data collection and analysis
Selection of studies
Two teams of three authors each (MC, MM and AS; OB, FP and
GF) independently assessed titles and abstracts to identify relevant
studies for inclusion. We obtained the full text of the study when
necessary to confirm inclusion. All completedRCTs,OLEs,CCTs,
and cohort studies were included if the studies contained clinically
relevant benefit and safety outcomes for any of the drugs included
in the review and met the inclusion criteria. The reference lists
of the articles were screened to identify any studies missed by
the electronic database search. Discrepancies in judgement were
resolved by discussion between review authors.
Data extraction and management
The six review authors extracted data independently and in du-
plicate using an Excel sheet piloted on three articles. We resolved
disagreements on extractions by discussion.
Outcome data
For all dichotomous outcomes, we extracted arm-level data (num-
ber of participants with events and number of participants). For
time to conversion to CDMS we extracted hazard ratios (HR) and
relative standard errors. When timing of outcome measure was
not reported at selected time points, we extracted data as close as
possible to that time point.When outcome data were not reported
or were unclear in the original article we checked reports from
the FDA or EMA. If necessary, we sought additional information
from the trial investigators. For non-randomised andOLE studies,
we preferred adjusted relative treatment effects to unadjusted.
Other extracted data
• Study design: year of publication, monocentric or
multicentric, recruitment period, time between onset of first
attack and randomisation method;
• Participants: age, gender, monofocal or multi-focal onset
presentation, type of first attack, baseline EDSS, baseline MRI
lesions, proportion of participants treated with steroids at the
first attack;
• Definitions of relapse and disability-worsening;
• Interventions: route, dose, frequency or duration of
treatment/follow-up.
In OLE studies we also extracted the number of participating
centres, and the number of participants who entered and com-
pleted the study during different follow-up times. For each non-
randomised study, we recorded the analysis method used to reduce
confounding.
Assessment of risk of bias in included studies
RCTs and OLEs
We assessed the risk of bias of each included study using the
Cochrane recommendations for assessment (Higgins 2011). These
included: random sequence generation, allocation concealment,
blinding of personnel and participants, blinding of outcome asses-
sors, incomplete outcome data, selective outcome reporting, and
evidence of major baseline imbalance. We explicitly judged the
risk of bias on each criterion as ’low’, ’high’ or ’unclear’. We judged
attrition as having low risk of bias when numbers and causes of
dropouts were balanced between arms. To summarise the qual-
ity of evidence we considered allocation concealment, blinding of
outcome assessors and incomplete outcome data to classify each
study as having low risk of bias (when all three criteria were judged
at low risk of bias), high risk of bias (when at least one criterion
was at high risk of bias), unclear risk of bias when all three criteria
were judged as having unclear risk of bias, and moderate risk of
bias in the remaining cases.
Participants in OLE studies were informed at the time they were
recruited into the RCT that they could be enrolled into an OLE
study. Then the participants taking placebo had the possibility
to switch to the active treatment when they were diagnosed with
CDMS or after they completed the RCT. The participant allo-
cated to the active treatment could decide to enter the OLE study
at the end of the RCT and continue taking the treatment. The
consequences of theOLE design were that original allocation con-
cealment was lost, participants entering the extension were clearly
selected, for example, those who had treatment benefit and did
not discontinue treatment due to adverse events.Moreover, partic-
ipants and outcome assessors were not blinded in the OLE phases.
For these reasons, we consideredOLE studies at high risk of bias for
random sequence generation, allocation concealment and blind-
ing of participants and outcome assessors. We reported the ’Risk
of bias’ assessments for RTC and OLE studies separately.
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Cohort studies
We assessed the risk of bias in the cohort studies using the
ROBINS-I tool for NRS (Sterne 2016) that includes the follow-
ing bias domains: confounding, selection of participants into the
study, classification of interventions, deviations from intended in-
terventions, missing data, measurement of outcomes and selection
of reported result. We judged each domain as pertaining to low,
moderate, serious, critical risk of bias or no information about risk
of bias and performed an overall ’Risk of bias’ assessment for each
study according to the criteria reported in the ROBINS-I tool for
NRS (Sterne 2016).
Adverse events
We evaluated the methods of monitoring and detecting adverse
events in each included study answering to the following two ques-
tions: firstly, did researchers actively monitor for adverse events, or
did they simply provide spontaneous reporting of adverse events
that arose; and secondly, did study authors define serious adverse
events according to an accepted international classification and
report the number of serious adverse events? (Singh 2011). We
have reported answers to these questions in a table ’Assessment of
adverse events monitoring, definition and reporting of serious ad-
verse events’. We used the resulting answers to decide indirectness
in GRADE.
MC, MM and AS independently assessed the risk of bias of each
RCT and OLE study and resolved disagreements by discussion.
OB, FP and GF independently assessed risk of bias of the cohort
studies and resolved disagreements by discussion. The final judg-
ments were established by GF and CDG.
Measures of treatment effect
We estimated, through pairwise meta-analysis, treatment effects
of competing interventions by using odds ratios (ORs) with 95%
confidence intervals (95% CIs) for each binary outcome at each
time point and HR with 95% CIs for conversion to CDMS. We
estimated the absolute effects for primary outcomes included in
the ’Summary of fIndings’ table. We presented the results from
NMA of RCTs as summary relative effect sizes according to the
type of outcome.
Unit of analysis issues
For multi-arm trials, intervention groups are all those that can be
included in a pairwise comparison of intervention groups, which,
if investigated alone, would meet the inclusion criteria. For exam-
ple, if a study compares ’interferon beta versus natalizumab ver-
sus interferon beta plus natalizumab’ only one comparison (’in-
terferon beta vs natalizumab’) addresses the review objectives. We
merged data from study arms involving the same drug at different
doses. For outcomes for which data were available as treatment
effects (i.e. HR), we used the data from the arm trial at highest
dose.
Dealing with missing data
We considered missing outcome data in the ’Risk of bias’ assess-
ment. In some of the studies included in the review, missing out-
come rates were considerable and we accounted for the their im-
pact on the outcomes assuming that they were not missing at
random. We assumed a relationship between the unknown out-
come among missing participants and the known outcome among
observed participants by using the ’informative missingness odds
ratios’ (IMORs) approach, allowing for uncertainty in the miss-
ing data imputations (Higgins 2008; White 2008). We assumed
in both groups that the odds of relapses or disability-worsen-
ing in missing participants were roughly 6 times times the odds
in the observed participants with 95% CI from 3 to 7 (IMOR
= 5.95, 95% CI 3 to 7). We set these values after discussion
with clinicians, who suggested that missing outcomes are most
probably unfavourable outcomes. To implement the approach we
used the ’metamiss’ command in Stata v14 (available from https:/
/www.mrc-bsu.cam.ac.uk/software/stata-software/).
Assessment of heterogeneity
In standard pairwise meta-analyses, we estimated different hetero-
geneity variances for each pairwise comparison. In NMA, we as-
sumed a common estimate for the heterogeneity variance for all
comparisons. We assessed the presence of statistical heterogeneity
within each pairwise comparison by visual inspection of the for-
est plots and by calculating the I2 statistic (Higgins 2003). The
type of drug used in the various studies was a suspected source
of heterogeneity and we performed all pairwise meta-analyses in
subgroups, considering the P value from the subgroup analyses as
an indication of differences between interventions.
Assessment of reporting biases
We were not able to assess the possibility of reporting bias as the
number of studies were fewer than 10 in all the analyses.
Data synthesis
We performed pairwise meta-analyses using a random-effects
model (using the Mantel-Haenszel estimator for Q) for any treat-
ment versus placebo and for early versus delayed treatment. We
performedNMAusing a random-effects model for outcomes eval-
uated in RCTs over 24 months of follow-up. The validity of net-
work estimates in NMA is based on the assumption of transitivity
(Salanti 2012). We had planned to assess whether the distribution
of potential effect modifiers (among those reported extracted data
in Data extraction and management) were balanced across com-
parisons (Jansen 2013), however, none of the networks that we
identified presented enough data to evaluate the assumptions. We
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conducted pairwise meta-analyses in Review Manager 5 (RevMan
5) software (RevMan 2017) and NMA in Stata v14 using the net-
work and network_graphs packages in Stata v14 (available from
https://www.mrc-bsu.cam.ac.uk/software/stata-software/).
Subgroup analysis and investigation of heterogeneity
We used the test for subgroup differences to assess the statisti-
cal heterogeneity across comparisons with different active agents
within standard pairwise meta-analyses. In the context of NMA,
we did not have enough information to assess incoherence, defined
as the statistical disagreements between direct and indirect effect
sizes, as only indirect evidence was available.
Sensitivity analysis
We re-ran the analyses of excluding observational studies when
relevant.
’Summary of findings’ table
We have presented the main results of the review in two ’Sum-
mary of findings’ tables, according to recommendations provided
in Chapter 11 of the Cochrane Handbook for Systematic Reviews of
Interventions (version 5.1.0) (Schunemann 2011). We judged the
credibility of the evidence from pairwise meta-analysis in accor-
dance with themethods of theGRADEWorkingGroup (GRADE
Working Group 2004). For each outcome the assumed risk in the
control group was based on the proportion of events in the in-
cluded studies.
In the first ’Summary of findings’ tablewe included an overall grad-
ing of the evidence for four patient-important outcomes with re-
gards to the review question ’Are disease-modifying drugs for a first
attack suggestive of MS effective and safe compared to placebo?’
• Disability-worsening during 24 months of treatment
• Relapse during 24 months of treatment
• Occurrence of at least one serious adverse event during 24
months of treatment
• Withdrawing from the study or discontinuing the drug due
to adverse events during 24 months of treatment
In the second ’Summary of findings’ table we included an overall
grading of the evidence for two patient-important outcomes with
regards to the review question ’Is early treatment with disease-
modifying drugsmore efficacious and safe than delayed treatment?
’
• Disability-worsening at a maximum of five years’ follow-up
from randomisation
• Relapse at a maximum of five years’ follow-up from
randomisation
R E S U L T S
Description of studies
Results of the search
Aflowdiagramdescribes the results of the electronic search (Figure
1).
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Figure 1. Study flow diagram.DMD: disease-modifying drugs; OLEs: open label extension studies; RCTs:
randomised controlled trials
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Included studies
Characteristics of included studies and Table 1 provide details
on the characteristics of the included studies. We included 10
RCTs involving 3745 participants and published between 2000
and 2014 (Achiron 2004; BENEFIT 2006; CHAMPS 2000;
ETOMS 2001; Motamed 2007; ORACLE 2014; Pakdaman
2007; PRECISE 2009; REFLEX 2012; TOPIC 2014); eight
OLEs involving 1868 participants and published between 2006
and 2016 (BENEFIT 2007 (3 years FU); BENEFIT 2009 (5 years
FU); BENEFIT 2014 (8.7 years FU); BENEFIT 2016 (11 years
FU); CHAMPS 2006 (5 years FU); CHAMPS 2012 (10 years
FU); PRECISE 2013 (5 years FU); REFLEX 2016 (3 and 5 years
FU)); and four cohort studies involving 4775 participants and
published between 2010 and 2016 (ACISS 2010; GERONIMUS
2013; MSBASIS 2016; Tintore 2015).
All RCTs were placebo-controlled studies with a median of two
years follow-up. Six (60%) of the 10 included RCTs assessed in-
terferons in people with a first attack suggestive of MS. BENEFIT
2006 provided data of four OLEs at maximum follow-up of three,
five, eight and 11 years from randomisation (BENEFIT 2007 (3
years FU); BENEFIT 2009 (5 years FU); BENEFIT 2014 (8.7
years FU); BENEFIT 2016 (11 years FU)); CHAMPS 2000 pro-
vided data of two OLEs with a maximum follow-up of five and 10
years (CHAMPS 2006 (5 years FU); CHAMPS 2012 (10 years
FU)); PRECISE 2009 provided data of one OLE with a maxi-
mum follow-up of five years (PRECISE 2013 (5 years FU)); and
REFLEX 2012 provided data of two OLEs with at maximum fol-
low-up of three and five years (REFLEX 2016 (3 and 5 years FU)).
Follow-up of the cohort studies ranged from two to six years.
We identified two ongoing cohort studies (NCT01371071;
NCT01013350). We will include these studies in a future update
of this review. Characteristics of ongoing studies provides details
on the characteristics of the two studies.
Excluded studies
After full-text review we excluded 26 studies (see Characteristics
of excluded studies): 14 studies reported sub-analysis of origi-
nal trials (BENEFIT 2007; BENEFIT 2008; BENEFIT 2011;
BENEFIT 2012; BENEFIT 2014a; CHAMPS 2001; CHAMPS
2002a; CHAMPS 2002b; CHAMPS 2002c; CHAMPS 2003;
ETOMS 2003; Filippi 2004; REFLEX 2014a; REFLEX 2014b)
and four studies reported re-analysis of original trials (BENEFIT
2014b; CHAMPIONS 2015; CHAMPS 2009; Moraal 2009); in
four studies participants with a first clinical attack suggestive of
MS were not reported separately from participants with relapsing-
remitting MS at the time of their first disease-modifying drugs
commencement (Meyniel 2012; Mowry 2009; MSBASIS 2015;
SWISS COHORT STUDY 2013); two studies did not include
efficacy or safety outcome (Curkendall 2011; SWISS COHORT
STUDY 2016); one cohort study did not evaluate disease-modi-
fying drugs (Kuhle 2015); and one study reported a cohort model
based on characteristics of participants enrolled into the BENE-
FIT trial (Lazzaro 2009).
Risk of bias in included studies
The risk of bias assessments are summarised separately for RCTs
and OLEs in Figure 2. Details on the judgement for each RCT
and OLE study and the reason for that judgement are reported
in Characteristics of included studies. Risk of bias in the included
cohort studies was assessed by ROBINS-I and it is reported in
Table 2.
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Figure 2. Review authors’ judgements about each risk of bias item presented as percentages across all
included studies and review authors’ judgements about each risk of bias item for each included study
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RCTs
Random sequence generation
Eight out of 10 RCTs (80%) reported adequate methods for al-
location sequence and we judged them to be at low risk of bias.
Two RCTs (20%) did not provide enough information to assess
allocation sequence and we judged the risk of bias to be unclear
for these studies.
Allocation concealment
Four out of 10 RCTs (40%) reported adequate methods for allo-
cation concealment and we judged them to be at low risk of bias.
Six RCTs (60%), did not provide enough information to assess
allocation concealment and we judged the risk of bias to be unclear
for these studies.
Other major baseline imbalance
Eight out of 10 RCTs (80%) were adequate in terms of baseline
balance and we judged them to be at low risk of bias. Two RCTs
(20%) did not provide enough information to assess the presence
of other baseline imbalance and we judged the risk of bias to be
unclear for these studies.
Blinding of participants and personnel
Only one RCT (10%) reported adequate methods for blinding
participants and personnel to treatment allocation. Two RCTs
(20%) did not provide enough information and we judged the
risk of bias to be unclear for these studies. We judged seven RCTs
(70%) to be at high risk of bias (BENEFIT 2006; ETOMS 2001;
Motamed 2007; ORACLE 2014; PRECISE 2009; REFLEX
2012; TOPIC 2014).
Blinding of outcome assessors
Four out of 10 RCTs (40%) reported adequate methods for blind-
ing outcome assessors to treatment allocation. Five RCTs (50%)
did not provide enough information and we judged the risk of bias
to be unclear for these studies. We judged one open-label study to
be at high risk of bias for blinding of outcome assessors (Motamed
2007).
Incomplete outcome data
We judged four out of 10 RCTs (40%) to be at low risk of bias
because missing outcome data were balanced in numbers across
intervention groups with similar reasons for missing data across
groups. Two (20%) studies (Motamed 2007; Pakdaman 2007) re-
ported insufficient information so that it was uncertain whether or
not the handling of incomplete data was appropriate. We judged
risk of bias for these two trials to be unclear. We judged four tri-
als (40%) to be at a high risk of bias, of which three (CHAMPS
2000; ORACLE 2014; PRECISE 2009) were stopped before the
scheduled period of follow-up because the studies had ended pre-
maturely and a low percentage of participants completed the stud-
ies. The fourth study (TOPIC 2014) showed more than 40% of
participants lost to follow-up.
Selective outcome reporting
We judged the majority of included studies (six of 10; 60%) to
be at low risk of bias. The study protocols were available or the
published reports included those outcomes that had been pre-
specified in themethods section of primary articles. One study did
not provide enough information to assess this item and the risk
of bias was judged to be unclear. In three trials (30%), we judged
risk of bias to be high (Achiron 2004; ORACLE 2014; Pakdaman
2007).
Method of adverse event monitoring
Five included trials (5 out of 10; 50%) reported that adverse events
were actively monitored. Four trials (40%) reported insufficient
information about the method of adverse events monitoring so
that it was uncertain whether or not adverse events were moni-
tored appropriately. CHAMPS 2000 reported adverse events only
during the first six months of treatment (Table 3).
Serious adverse event definitions
The majority of included studies (7 out of 10; 70%) gave insuf-
ficient information on serious adverse events definition, the re-
maining three trials (30%) provided this definition (Table 3).
OLEs
Random sequence generation
We judged all eight OLEs to be at high risk of bias for sequence
generation because there was no random assignment to the open-
label treatment groups.
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Allocation concealment
We judged all eight OLEs to be at high risk of bias because there
was no allocation concealment with respect to assignment to the
open-label treatment groups.
Other major baseline imbalance
Two out of eight OLEs (25%) were adequate in terms of baseline
balance and we judged them to be at low risk of bias. Six OLEs
(75%) did not provide enough information to assess the presence
of other baseline imbalance and we judged the risk of bias to be
unclear for these studies.
Blinding of participants and personnel
None of the eightOLEs blinded participants or personnel to treat-
ment allocation. We judged these studies to be at high risk of bias
for blinding of participants and personnel.
Blinding of outcome assessors
None of the eight OLEs blinded outcome assessors to treatment
allocation. We judged these studies to be at high risk of bias for
blinding of outcome assessors.
Incomplete outcome data
Seven (87%) of the eight OLEs were likely to be at high risk of
attrition bias as participants who dropped out ranged from23% to
70% and proportions and reasons of missing participants differed
substantially across intervention groups. Most of the participants
who were lost to follow-up may have not responded in the original
RCT or have had adverse events that were not included in the
analyses, which could overestimate the treatment benefit or un-
derestimate the adverse effect estimates. In one OLE (BENEFIT
2007 (3 years FU)) the majority of participants (about 80%) con-
tributed outcome data and thus we judged this study to be at low
risk of attrition bias.
Selective outcome reporting
We judged most of the included studies (six of eight; 75%) to be
at high risk of selective reporting bias. We did not find study pro-
tocols in the ClinicalTrials.gov database or in the FDA or EMA
databases, and judged published reports to be at high risk of this
type of reporting bias if they did not report all expected outcomes,
including treatment discontinuation due to adverse events or se-
rious adverse events, that were primary outcomes pre-specified in
the methods section. The six OLEs were likely to be at high risk
of selective reporting bias because these studies did not specify
in the methods that they intended to report adverse events and
treatment discontinuation due to adverse events or serious adverse
events were not reported.
Method of adverse event monitoring
All the included OLEs reported insufficient information to judge
if adverse events were monitored appropriately or not (Table 3).
Serious adverse event definitions
All the includedOLEsdidnot clearly define ‘serious adverse events’
(Table 3).
Cohort studies
We assessed risk of bias according to ROBINS-I tool for non-
randomised studies of interventions (Sterne 2016).We judged two
(ACISS 2010;MSBASIS 2016) of the four included cohort studies
at critical risk of bias, and the other two studies (GERONIMUS
2013; Tintore 2015) at serious risk of bias (Table 2). None of
the cohort studies reported the method they used to monitor and
detect adverse events or to define serious adverse events (Table 3).
Effects of interventions
See: Summary of findings for the main comparison Are
disease-modifying drugs for a first attack suggestive of multiple
sclerosis (MS) effective and safe compared to placebo?; Summary
of findings 2 Is early treatmentwith disease-modifying drugsmore
efficacious and safer than delayed treatment?
Research question 1: is early treatment efficacious
and safe compared to placebo or no treatment?
Ten RCTs and two cohort studies compared early intervention
versus placebo or no treatment.
Their results are synthesised and presented in Summary of findings
for the main comparison.
Primary outcomes
Disability-worsening
The number of participants who had disability-worsening during
24 months was available from two RCTs (ETOMS 2001, TOPIC
2014) and 927 participants (25% of those included in the 10
RCTs). The summary OR, which takes into account the missing
outcome data, suggested a non-significant reduction of the odds
of disability-worsening in early treatment with interferon beta-
1a (Rebif®) (ETOMS 2001) or teriflunomide (TOPIC 2014)
comparedwith placebo (OR0.74, 95%CI0.49 to 1.14, P =0.696)
with very little heterogeneity (I² = 0%) (Figure 3). In one cohort
study (ACISS 2010) participants treated with disease-modifying
drugs at their first attack had greatermean score of EDSSmeasured
at 24 months than participants who were never treated (Table 4).
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Figure 3. Forest plot of comparison: treatment with disease-modifying drugs compared with placebo.
Random-effects meta-analysis results of proportion of participants with disability-worsening over 24 months in
RCT studies. We assumed in both groups that the odds of disability-worsening in missing participants were
5.95 times the odds in the observed participants with 95% CI from 3 to 7
Relapses
Data from only one trial (TOPIC 2014) with 618 participants
(16.5%) were available to calculate the number of participants
who continued to have relapses during the first 24 months of
treatment with teriflunomide. The result obtained applying the
IMORmethod indicated a lower but not significant odds of relapse
compared to placebo (OR 0.65, 95% CI 0.38 to 1.12). In one
cohort study (ACISS 2010) there was no difference during the
first 24 months of treatment in the number of relapses among
participants who took disease-modifying drugs for their first attack
compared to participants who were not treated (Table 4).
Occurrence of at least one serious adverse event
Data on adverse events over 24 months were available from
seven RCTs (BENEFIT 2006; CHAMPS 2000; ETOMS 2001;
ORACLE 2014; PRECISE 2009; REFLEX 2012; TOPIC 2014)
(3385 participants; 90%).The summary OR was 0.78 (95% CI
0.60 to 1.03, P = 0.08) (Analysis 1.1) suggesting, with very little
heterogeneity (I2 = 0%), that the odds of occurrence of at least
one serious adverse event were lower in the active interventions
compared with placebo. One trial (Pakdaman 2007) with 202 par-
ticipants (5%) suggested that the odds of occurrence of at least
one serious adverse event were greater with interferon beta 1-a
(Avonex®) compared with placebo over 36 months of follow-up;
however this difference was very imprecise (OR 1.23, 95% CI
0.44 to 3.45, P = 0.69, Analysis 1.2).
Withdrawing from the study or discontinuing the drug due
to adverse events
Data from five RCTs (BENEFIT 2006; ORACLE 2014;
PRECISE2009;TOPIC2014;REFLEX2012)with 2693partici-
pants (72%)were reported for this outcome over 24months.Over-
all, treatment was associated with greater odds of withdrawal or
discontinuation compared with placebo (OR 2.43, 95% CI 0.91
to 6.49, P = 0.08) (Analysis 1.3). There was considerable hetero-
geneity (I² = 78%); compared to placebo, interferon beta 1-b (Be-
taseon®) (BENEFIT 2006), glatiramer acetate (PRECISE 2009)
and cladribine (ORACLE 2014) were associated with significantly
more withdrawals due to adverse events, while interferon beta-
1a (Rebif®) (REFLEX 2012) and teriflunomide (TOPIC 2014)
were not significantly different from placebo. Interferon beta 1-
a (Avonex®) was shown to be associated with fewer withdrawals
and discontinuations compared with placebo during the first 12
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months of treatment (OR 0.14, 95%CI 0.02 to 1.12) (CHAMPS
2000) (Analysis 1.4).
Secondary outcomes
Time to conversion to CDMS
Seven RCTS reported this outcome at 24 months (BENEFIT
2006; CHAMPS 2000; ETOMS 2001; ORACLE 2014;
PRECISE 2009; REFLEX 2012; TOPIC 2014) (3385 partici-
pants; 90%) and in two cohort studies (ACISS 2010; MSBASIS
2016) with 3592 participants (75% of those included in the four
cohort studies). Overall there was a significant advantage of early
treatment compared to control groups in reducing the hazard of
CDMS during the first 24 months of treatment (HR 0.53, 95%
CI 0.47 to 0.60; P < 0.001). There was no evidence of heterogene-
ity (I² = 0%) (Analysis 1.5). Immunoglobulins (Achiron 2004)
were associated with a significantly lower hazard to conversion
compared with placebo during the first 12 months of treatment
(HR 0.36, 95% CI 0.15 to 0.86; P = 0.02, Analysis 1.6).
Withdrawing from the study or discontinuing the drug for
any reason
Data at 24monthswere available from sixRCTs (BENEFIT 2006;
CHAMPS 2000; ETOMS2001;ORACLE2014; REFLEX 2012;
TOPIC 2014) (2931 participants; 78%). On average placebo and
active drugs showed similar odds of discontinuation and dropout
(OR 1.00, 95% CI 0.61 to 1.62, P = 0.99, Analysis 1.7) but there
was considerable heterogeneity (I² = 84%). Compared to placebo,
interferonbeta 1-b (Betaseron®) (BENEFIT 2006) and cladribine
(ORACLE 2014) were associated with a greater proportion of
participants who discontinued treatment or were lost to follow-up
for any reason (OR 1.50, 95% CI 0.95 to 2.3; OR 2.30, 95% CI
1.49 to 3.56), while interferon beta 1a (Rebif®) and teriflunomide
were on average better than placebo. One study showed a very
imprecise advantage of placebo over immunoglobulins (Achiron
2004) during the first 12 months of treatment (OR 2.15, 95% CI
0.37 to 12.35, Analysis 1.8).
Research question 2: are there differences in efficacy
and safety between the various drugs administered as
early treatments?
To examine the comparative effect of one disease-modifying drug
against another we considered the results from theNMA of RCTs.
Evidence was scarce and the assumptions underlying NMA im-
possible to evaluate.
Primary outcomes
Disability-worsening
Only two RCTs reported this outcome over 24months, one for in-
terferon beta-1a (Rebif ®) (ETOMS 2001) and one for terifluno-
mide (TOPIC 2014) compared to placebo. Indirect comparison
did not indicate a difference between the interventions (interferon
beta-1a (Rebif ®) versus teriflunomide: OR 0.84 95% CI 0.43 to
1.66) in reducing disability-worsening.
Relapses
Only one study was available for teriflunomide compared with
placebo over 24 months (TOPIC 2014).
Occurrence of at least one serious adverse event
There were no important differences between active drugs with
respect to the odds of serious adverse events. The effect sizes
from studies examining various drugs were not heterogeneous (in
Analysis 1.1, I² = 0% and P = 0.72 for subgroup differences). We
did not estimate relative treatment effects between active drugs in
an NMA because there was important variation in the definition
of serious adverse events violating the transitivity assumption.
Withdrawing from the study or discontinuing the drug due
to adverse events
We identified important differences between the drugs, as shown
in Analysis 1.3 (test for subgroup differences P = 0.003). The
ORs between active drugs estimated from NMA along with the
network plot are shown in Figure 4. As only one study per com-
parison was available the results pertain to a fixed-effect model.
Two treatments, interferon beta-1a (Rebif®) and teriflunomide,
were associated with significantly fewer withdrawals or discontin-
uation due to adverse events compared to other treatments. Odds
of withdrawing from the study or discontinuing Rebif® were sig-
nificantly lower compared with Betaseron® (OR 0.03, 95% CI
0.00 to 0.33), cladribine (OR 0.18, 95% CI 0.04 to 0.79) and
glatiramer acetate (OR 0.21, 95% CI 0.04 to 0.96). Terifluno-
mide presented fewer withdrawals and discontinuations than Be-
taseron® (OR 0.05, 95% CI 0.01 to 0.38), cladribine (OR 0.25,
95% CI 0.07 to 0.82) and glatiramer acetate (OR 0.29, 95% CI
0.08 to 1.01). All these estimates have large variations around
them. As only placebo-controlled trials were available we were un-
able to evaluate the plausibility of the transitivity assumption and
hence the confidence in the results from NMA is very low.
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Figure 4. Network plot of comparisons and network meta-analysis estimates for the proportion of
participants who withdrew from the study because of adverse events in RCT studies. The estimate is located
at the intersection of the column-defining treatment and the row-defining treatment. In the lower triangle the
comparisons should be read from left to right, a OR value less than 1 favours the column-defining treatment.
In the upper triangle the comparisons should be read from right to left, a OR value larger 1 favours the row-
defining treatment. Significant results are in italic
Secondary outcomes
Time to conversion to CDMS
All interventions were associated with beneficial effects compared
with placebo and there were no significant differences between
them (test for subgroup differences P = 0.79, Analysis 1.5). This
was confirmed by a NMA synthesising data over 24 months (
Figure 5). Note that we were unable to evaluate the transitivity
assumption because few studies and only indirect comparisons
were available, and hence NMA results have low credibility.
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Figure 5. Network plot of comparisons and network meta-analysis estimates for the time to conversion to
CDMS in RCT studies over 24 months. The estimate is located at the intersection of the column-defining
treatment and the row-defining treatment. In the lower triangle the comparisons should be read from left to
right, a HR value less than 1 favours the column-defining treatment. In the upper triangle the comparisons
should be read from right to left, a HR value larger than 1 favours the row-defining treatment. Significant
results are in italic
Withdrawing from the study or discontinuing the drug for
any reason
Important differences existed between drugs with respect to the
odds of discontinuing or withdrawing from the study for any rea-
son (test for subgroup differences P = 0.005, Analysis 1.7). The
network plot and results from NMA are presented in Figure 6.
Indirect comparisons were very imprecise due to the low number
of events. Note that we were unable to evaluate the transitivity as-
sumption because few studies and only indirect comparisons were
available, and hence NMA results have very low credibility.
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Figure 6. Network plot of comparisons and network meta-analysis estimates for the proportion of
participants who discontinued treatment and were followed up to the end of the study or who were lost to
follow-up for any reason in RCT studies. The estimate is located at the intersection of the column-defining
treatment and the row-defining treatment. In the lower triangle the comparisons should be read from left to
right, a HR value less than 1 favours the column-defining treatment. In the upper triangle the comparisons
should be read from right to left, a HR value larger 1 favours the row-defining treatment
Research question 3: is early treatment more
effective and safe than delayed treatment?
Eight OLE studies provided data for this comparison. Delayed
treatment was defined as treatment given only after a second clin-
ically confirmed attack or at two years after randomisation. The
study-specific time until the delayed treatment after randomisa-
tion is presented in Table 5. In the description of results below,
the follow-up time is the time after randomisation.
The results are synthesised and presented in Summary of findings
2.
Primary outcomes
Disability-worsening
Data were available at a maximum of three (BENEFIT 2007 (3
years FU); REFLEX 2016 (3 and 5 years FU)), five (CHAMPS
2006 (5 years FU); BENEFIT 2009 (5 years FU); PRECISE 2013
(5 years FU); REFLEX 2016 (3 and 5 years FU)), 8.7 (BENEFIT
2014 (8.7 years FU)), 10 and 11 years of follow-up (CHAMPS
2012 (10 years FU); BENEFIT 2016 (11 years FU)). We under-
took data synthesis accounting for the large amounts of missing
outcome data. Overall, the benefit of early compared to delayed
treatment was very imprecise with high heterogeneity (Figure 7).
Early treatment with interferon beta-1b (Betaseron®) appeared to
significantly reduce the odds of participants with disability-wors-
ening compared with delayed treatment at a maximum of three
andfive years’ follow-up (BENEFIT 2007 (3 years FU); BENEFIT
2009 (5 years FU)). Results of the REFLEX 2016 (3 and 5 years
FU) study suggested a non-significant reduction of the odds of par-
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ticipants with disability-worsening in delayed compared with early
treatment with interferon beta-1a (Rebif®) at amaximum of three
and five years’ follow-up. Results on interferon beta-1a (Avonex®)
(CHAMPS 2006 (5 years FU); CHAMPS 2012 (10 years FU)) or
glatiramer acetate (PRECISE 2013 (5 years FU)) were imprecise.
We did not include the outcome data for interferon beta-1b (Be-
taseron®) during 11 years’ follow-up (BENEFIT 2016 (11 years
FU)) in the analysis as this was a cross-sectional reassessment of the
original RCT (investigators conducted participant assessments at
their respective centers or via a structured interview by phone) and
not appropriate to be combined with the other data (OR 0.82,
95% CI 0.46 to 1.47, as estimated from the original study data).
One cohort study (Tintore 2015) reported that participants who
received early treatment had a lower hazard of attaining an EDSS
score of 3.0 compared with delayed treatment (adjusted HR 0.5,
95% CI 0.3 to 0.9) during a mean follow-up time of three years
and nine months (Table 4).
Figure 7. Forest plot of comparison: early treatment compared with delayed treatment with disease-
modifying drugs. Random-effects meta-analysis results of proportions of participants with disability-worsening
at a maximum of 3 years, 5 years and 10 years of follow-up in open-label extension studies. We assumed in
both groups that the odds of disability-worsening in missing participants were 5.95 times the odds in the
observed participants with 95% CI from 3 to 7
Relapses
Data at a maximum of five years’ follow-up were available in three
OLE studies.We undertook data synthesis accounting for the large
amounts of missing outcome data. Early treatment with inter-
feron beta 1-b (BENEFIT 2009 (5 years FU)), interferon beta 1-a
(Rebif®) (REFLEX 2016 (3 and 5 years FU)) and glatiramer ac-
etate (PRECISE 2013 (5 years FU)) significantly reduced the odds
of participants with relapses compared to delayed treatment (OR
0.35, 95% CI 0.26 to 0.48, I² = 0.0%) (Figure 8). At a maximum
of three years’ follow-up early treatment with interferon beta 1-a
(Rebif®) (REFLEX 2016 (3 and 5 years FU)) decreased the odds
of participants with relapse compared to delayed treatment (OR
0.51, 95% CI 0.33 to 0.81). Between five and 10 years’ follow-
up, the early interferon beta 1-a (Avonex®) group was less likely
than the delayed group to experience relapses (OR 0.51, 95% CI
0.25 to 1.04) (CHAMPS 2012 (10 years FU)).
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Figure 8. Forest plot of comparison: Early treatment compared with delayed treatment with disease-
modifying drugs. Random-effects meta-analysis results for proportion of participants with relapse over 5 years
follow-up in OLE studies. We assumed in both groups that the odds of relapses in missing participants were
5.95 times the odds in the observed participants with 95% CI from 3 to 7
Occurrence of at least one serious adverse event
Definition of serious adverse events according to an accepted in-
ternational classification was not specified in any of theOLE stud-
ies and there was important variation across studies. Additionally,
the process of including participants in the OLE phases was likely
associated with the occurrence of adverse events and hence the risk
of selections bias was very high. Consequently, we presented the
data as reported in the studies in Table 6 but we did not draw any
conclusions.
Withdrawing from the study or discontinuing the drug due
to adverse events
Themethod of monitoring adverse events was not specified in any
of the extension studies and there was varying reliability of the dif-
ferent monitoring approaches. For these reasons and because there
was selection of participants in the extension studies we presented
results in Table 6 only and we did not draw any conclusions.
Secondary outcomes
Time to conversion to clinically definite multiple sclerosis
Early treatment with any drug reduced the hazard to conversion to
CDMS over any follow-up period (Analysis 2.1). Summary hazard
ratios were 0.62 (95% CI 0.48 to 0.81, I² = 0%) from five studies
reporting the outcome at a maximum follow-up between two and
four years, 0.62 (95% CI 0.53 to 0.73, I² = 0%) from four studies
reporting the outcome at a maximum of five years and 0.65 (95%
CI 0.54 to 0.79, I² = 0%) from two studies reporting the outcome
between 8.7 and 10 years. This beneficial effect of early treatment
was also present for longer follow-up; BENEFIT 2016 (11 years
FU) reported an HR of 0.67 (95% CI 0.53 to 0.85) at 11 years
(this result was not included in the meta-analysis for the same
reason explained above).
Withdrawing from the study or discontinuing the drug for
any reason
In OLE studies participants were selected according to their will-
ingness to take an active intervention or continue with the active
intervention they were initially randomised to and hence this out-
come cannot be measured. We presented results reported in these
studies in Table 6 but we did not draw any conclusions.
Subgroup and sensitivity analyses
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We conducted the simple meta-analysis for the conversion to
CDMS for the first and third research question excluding cohort
studies. In both cases the conclusions did not change compared
with the main analyses (HR 0.53, 95% CI 0.46 to 0.61 and HR
0.58, 95% CI 0.46 to 0.73, respectively).
A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Patient: adults with f irst attack suggest ive of MS
Setting: MS centres
Intervention: early disease-modif ying drug treatment
Comparison: delayed disease-modif ying drug treatment; af ter the second attack or diagnosis with clinically def init ive MS
Outcomes Relative effect
(95% CI)
Anticipated absolute effects∗ (95% CI) Quality of the evidence
(GRADE)
What happens
Without early disease-
modifying drug treat-
ment
With early disease-
modifying drug treat-
ment
Difference
Disability-worsening
Proport ion of part ici-
pants with disability-
worsening at a max-
imum of f ive years’
follow-up (assessed by
EDSS* * )
Part icipants: N = 1868
(4 open-label extension
studies)
OR 0.88
(0.50 to 1.57)
40.2% 37.2%
(25.2 to 51.4)
3.0% fewer
(15 fewer to 11.1 more)
⊕©©©
Very lowa,b,c,d
No signif icant ef fect
of early treatment
compared to delayed
treatment during f ive
years’ follow-up; how-
ever there is a signif i-
cant heterogeneity be-
tween the studies
Relapse
Proport ion of part ici-
pants with relapse at a
maximum of f ive years’
follow-up
Part icipants: N = 1485
(3 open-label extension
studies)
OR 0.35
(0.26 to 0.48)
83.4% 63.8%
(56.7 to 70.7)
19.6% fewer
(26.7 fewer to 12.7
fewer)
⊕⊕©©
Lowa
Early treatment re-
duced the risk of re-
lapses compared to de-
layed treatment during
f ive years’ follow-up
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* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
* * EDSS: expanded disability status scale
CI: Conf idence interval; OR: Odds rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aHigh risk of bias for allocat ion concealment, blinding of outcome assessment and incomplete outcome data.
bSurrogate outcome in two out of four studies contribut ing to this est imate.
cHigh heterogeneity (I² = 67%, P = 0.03).
dThe conf idence interval fails to exclude important benef it or important harms.
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D I S C U S S I O N
Summary of main results
We analysed all RCTs and open-label extension studies undertaken
so far on the use of disease-modifying drugs in participants with a
first clinical attack. The review included ten RCTs (3745 partici-
pants) with a median of two years’ follow-up, and eight open-la-
bel extension studies (1868 participants) ranging from three to 11
years’ follow-up. Most extension studies had major methodolog-
ical shortcomings. The most common flaws were lack of blind-
ing of outcome assessors and high dropout rates, combined with
failure to do an intention-to-treat analysis, even though most tri-
alists specifically declared their intention to do such an analysis.
The review also included four cohort studies involving 4775 par-
ticipants. These cohort studies had serious defects and we judged
them to be at critical or serious risk of bias by the ROBINS-I tool.
Disability-worsening
Is early treatment efficacious and safe compared to placebo
or no treatment?
Data were available from two RCTs. The odds of disability-wors-
ening decreased but were not significantly reduced during the first
24 months of interferon beta-1a (Rebif®) or teriflunomide treat-
ment compared to placebo. A small cohort study showed a greater
mean score of EDSS measured at 24 months’ follow-up in partic-
ipants receiving an early treatment compared with those who did
not receive any treatment.
Are there differences in efficacy and safety between the
various drugs administered for early treatment?
There was not enough evidence to answer this question with con-
fidence.
Is early treatment better than delayed treatment?
Information to answer this question for disability-worsening was
available in the open-label extension studies of four RCTs. The
available evidence indicated a protective effect of early treatment
with interferon beta-1b (Betaseron®) compared with delayed
treatment during three and five years’ follow-up. Early treatment
with interferon beta-1a (Rebif®), interferon beta-1a (Avonex®),
or glatiramer acetate was not beneficial compared to delayed treat-
ment at any time of follow-up. It is not clear from our analysis
why this may be although in view of the great variability of the in-
cluded extension studies these findings should be interpreted with
caution. Early treatment with interferon beta-1b (Betaseron®) or
interferon beta-1a (Avonex®) was no different from delayed treat-
ment in terms of the proportion of participants who had disabil-
ity-worsening during 10 years’ follow-up.
Relapses
Is early treatment efficacious and safe compared to placebo
or no treatment?
In a single trial the odds of relapses were less but not signifi-
cantly smaller with early teriflunomide treatment compared with
placebo. In one cohort study relapses were not reduced in partic-
ipants on early disease-modifying drugs compared with partici-
pants who were not treated.
Are there differences in efficacy and safety between the
various drugs administered for early treatment?
There was not enough evidence to answer this question with con-
fidence.
Is early treatment better than delayed treatment?
The results of open-label extension studies showed that early treat-
ment was associated with lower odds of recurrence of relapses dur-
ing three and five years of follow-up.
Occurence of at least one serious adverse event
Is early treatment efficacious and safe compared to placebo
or no treatment?
Early treatment was associated with fewer chances of having at
least one serious adverse event compared with placebo, although
this difference was not significant. Information on serious adverse
events was scanty and poorly reported in the included randomised
trials.
Are there differences in efficacy and safety between the
various drugs administered for early treatment?
No evidence was available.
Is early treatment better than delayed treatment?
This review cannot conclude on long-term serious adverse events
because of inadequacies in the available data both in the included
open-label extension studies and cohort studies.
Treatment discontinuation or dropout due to adverse events
Is early treatment efficacious and safe compared to placebo
or no treatment?
Interferon beta 1-b (Betaseron®), glatiramer acetate, and cladrib-
ine were associated with significantly higher proportion of partic-
ipants who withdrew due to adverse events compared to placebo
during 24 months of treatment.
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Are there differences in efficacy and safety between the
various drugs administered for early treatment?
Indirect comparisons revealed that interferon beta 1-a (Rebif®)
and teriflunomide were associated with significantly lower propor-
tions of participants who withdrew due to adverse events com-
pared to interferon beta 1-b (Betaseron®), glatiramer acetate and
cladribine. The estimates are very uncertain and it is possible that
these differences reflect differences in the methods of monitoring
and recording adverse events across studies.
Is early treatment better than delayed treatment?
This review cannot conclude on long-term adverse events because
of inadequate data reported both in the included open-label ex-
tension studies and the cohort studies.
Conversion to CDMS
Is early treatment efficacious and safe compared to placebo
or no treatment?
Early treatment was associated with significantly lower hazard of
conversion to CDMS over 24 months of follow-up.
Are there differences in efficacy and safety between the
various drugs administered for early treatment?
Indirect comparisons and subgroup differences showed that the
disease-modifying drugs did not differ in their effects on efficacy
and safety.
Is early treatment better than delayed treatment?
Open-label extension studies and cohort studies showed that early
treatment reduced the hazard of conversion to CDMS at any fol-
low-up up to 10 years.
Treatment discontinuation or dropout for any reason
Is early treatment efficacious and safe compared to placebo
or no treatment?
Compared to placebo, interferon beta 1-b (Betaseron®), and
cladribine were associated with significantly higher proportion of
participants who discontinued treatment or were lost to follow-
up for any reason during 24 months of treatment. These results
are very uncertain therefore these findings should be interpreted
with caution.
Are there differences in efficacy and safety between the
various drugs administered for early treatment?
Indirect comparisons revealed that the disease-modifying drugs
did not differ from each other with regards to this outcome over 24
months of follow-up and it is possible that these differences reflect
differences in the methods of monitoring and recording adverse
events across studies.
Is early treatment better than delayed treatment?
This review cannot conclude on this outcome because of inad-
equate data reported both in the included open-label extension
studies and the cohort studies.
Overall completeness and applicability of
evidence
All eligible RCTs, their open-label extensions and cohort studies
up to December 2016 were included. Unfortunately, only a small
number of included studies reported data on the predefined pri-
mary outcomes of the review, that is, short- and long-term dis-
ability-worsening and recurrence of relapses. This is an unwel-
come finding considering that according to the new MS diagnos-
tic criteria (Polman 2011) most of the participants included in
this review currently receive a diagnosis of MS at their first attack
and they need evidence about benefit of early disease-modifying
treatment with regards to disability-worsening and recurrence of
relapses that are the most important outcomes. We decided to in-
clude open-label extension studies and cohort studies aiming to
collect evidence on the long-term safety of early treatment with
disease-modifying drugs, but unfortunately the studies included
in the review reported scanty and poorly detailed safety data that
did not allow us to draw conclusions, leading to uncertainty about
the long-term risk profile of these treatments.
Quality of the evidence
There were 10 RCTs with 3745 participants included in this re-
view. We only judged one of the included trials (10%) to be at low
risk of bias, when criteria for allocation concealment, blinding of
outcome assessors, and complete outcome data were met. In the
majority of trials, we judged allocation concealment to be ‘unclear’
due to lack of details provided in the study reports. Blinding of
outcome assessors was also not clearly described in many of the
included studies. We judged four studies to have a high risk of bias
for incomplete outcome data. Most studies were judged to have a
low risk of bias due to major baseline imbalances.
The majority of trials in this review did not provide sufficient in-
formation on how a serious adverse event was defined in the study.
We combined data on serious adverse events in pairwise meta-
analysis, regardless of the definition and whether it was provided,
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so caution is needed in interpreting this outcome. We assessed
whether trials reported undertaking active monitoring for adverse
events. Fifty percent of included trials reported that they moni-
tored for adverse effects, howevermany differentmonitoring tech-
niques may have been used with great variation of the different
approaches.
We included eight open-label extension studies (1868 partici-
pants) of four RCTs. Given the design of extension studies, in
which a highly selected group of participants continued on from
the RCT and the majority of participants and outcome assessors
were unblinded, we judged most of these studies to be at high risk
of bias. We also judged 90% of the included studies to be at high
risk of attrition bias because dropouts ranged from 23% to 70%
and proportions and reasons for missing participants differed sub-
stantially across intervention groups. Serious adverse events were
not clearly defined in most extension studies and the majority of
them reported insufficient information to judge if adverse events
were monitored appropriately or not.
We included four cohort studies with 4775 participants. We as-
sessed risk of bias of these studies according to ROBINS-I tool
for non-randomised studies of interventions (Sterne 2016). We
judged two studies at critical risk of bias, and the other two studies
at serious risk of bias. None of the included cohort studies defined
or reported serious adverse events, or whether adverse events were
monitored appropriately or not.
For the overall results of disease-modifying drugs as a group versus
placebo for the four primary outcomes of disability-worsening,
recurrence of relapse, serious adverse events and withdrawals due
to adverse events during 24 months of treatment, we graded our
confidence in the results as ’very low’ or ’low’ using the GRADE
approach (Summary of findings for the main comparison). For
the results of early treatment compared to delayed treatment for
the two primary outcomes of disability-worsening and recurrence
of relapses during five years’ follow-up, we graded our confidence
in the results as ’very low’ or ’low’ (Summary of findings 2).
Potential biases in the review process
This review has several differences compared to its protocol. We
have broadened the research question as a result of the identified
data. The initial protocol was focused on detecting differences
between the intervention (research question 2) but we realised
that we would not be able to answer this question and we added
two other aims that we considered clinically important. We also
added an outcome (time to conversion toCDMS). Although these
decisions were guided by data availability, we think that this has
not introduced bias in our review because its scope has become
wider rather than narrower.
Agreements and disagreements with other
studies or reviews
In this review that includedRCTsof sevendisease-modifyingdrugs
used inparticipantswhohad afirst clinical attack suggestive ofMS,
we found that participants who received interferons, glatiramer
acetate, teriflunomide, cladribine had significantly lower hazard
of conversion to MS compared to placebo and the effects of these
drugs did not differ from each other. Compared with placebo,
disease-modifying drugs did not increase the risk of serious ad-
verse events. Interferon beta 1-a (Rebif®) and teriflunomide were
associated with a lower risk of withdrawals due to adverse events,
compared with placebo and the other drugs.
Our findings extend the findings of a previous Cochrane Review
that examined only three RCTs of 24 months’ duration of inter-
feron beta 1-b (Betaseron®), interferon beta 1-a (Rebif®) and in-
terferon beta 1-a (Avonex®) (Clerico 2008). They reported that
interferons had lower-than-placebo risk of conversion to CDMS,
the frequency of serious adverse events was not significantly differ-
ent in interferon groups compared to placebo, but active treatment
was more likely than placebo to lead to withdrawals due to adverse
events. Similar observations have been made by one qualitative
review, Freedman 2014 of the same three RCTs of interferons. In
one review (Smith 2010) of five RCTs of disease-modifying drugs,
which included some of the same RCTs with their extensions dur-
ing five years’ follow-up, the authors concluded that all the three
interferons and glatiramer acetate reduced the probability of con-
verting from clinically isolated syndrome to CDMS over a pe-
riod of two to five years. They reported that the included studies
did not describe methods of ascertaining adverse events and that
their reporting was sparse. The incidence of adverse events was
significantly higher in the interferon and glatiramer acetate groups
compared with the placebo groups for most commonly occurring
adverse events such as influenza-like syndrome and injection-site
reactions. Rates of serious adverse events were no different from
placebo in any trial. Most of our findings from direct and indirect
comparisons cannot be compared to previous studies since most of
them reported only a qualitative description of the trials focusing
on efficacy outcomes.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Our study has several important findings but some conservative
interpretation of the results is warranted, since most of the in-
cluded treatments have been evaluated in few trials compared with
placebo and the overall quality of evidence is low or very low.
Weak evidence of low to very low quality suggests that early treat-
ment reduces the chances of recurrence or relapse compared to
placebo, no treatment or delayed treatment both in short- and
long-term follow-up. The benefit of early treatment for disability-
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worsening both in short- and long-term follow-up remains un-
clear.
There are indications that there might be differences in the short-
term safety of the disease-modifying drugs included in this review,
but it is not possible to pinpoint them with the available studies.
This review cannot conclude on long-term safety of these drugs
when administered as early treatment because of inadequately-
reported or unavailable data. Until convincing evidence of any
difference on benefit between disease-modifying drugs becomes
available, the drugs that have been in use in clinical practice for
many years and with a safety profile that is well understood, are
probably the most sensible choice for early treatment.
Implications for research
There are two needs that the research agenda should address. First,
randomised trials of direct comparisons between active agents
would be useful, avoiding further placebo-controlled studies that
do not now comply with the principle of clinical equipoise for
treatment of multiple sclerosis (MS). Second, long-term bene-
fit and safety of early treatment with disease-modifying drugs
and comparative benefit and safety of different disease-modifying
drugs should be mandatory. As the number of disease-modifying
drugs that are available for treatment of MS increases, more op-
tions are available to people with MS and clinicians. In the ab-
sence of comparative trials, national and international registries
and other types of large databases may be relevant sources for pro-
viding complementary data regarding the long-term benefit and
safety of disease-modifying drugs for MS.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Achiron 2004
Methods RCT, parallel-group.Recruitment period:March 1998-March 2003.Countries: 1 (Israel)
. Centres: 1
Participants N = 91. Women 74%. Age, mean (range): 34 years (15-50 years)
Participants with a first neurological episode suggesting MS in the previous 3 months.
They had positive brain MRI according to Fazekas criteria
Interventions Immunoglobulins 0.4 g/kg body weight intravenously daily for 5 consecutive days fol-
lowed by additional booster doses of immunoglobulins 0.4 g/kg body weight intra-
venously daily once every 6 weeks for a period of 12 months (N = 45)
Placebo (0.9% saline) intravenously monthly for 12 months (N = 46)
Outcomes Conversion to CDMS, i.e. number of participants who experienced a second attack
within 12 months
Notes The study was supported by a research grant from Omrix Biopharmaceuticals, Tel-Aviv,
Israel, which also supplied the study drugs. The authors have no financial relationship to
Omrix Biopharmaceuticals. All authors had full access to all the data and had the right
to publish all the data. The data were analysed by an independent statistician (p 1519-
20)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Ablock-stratified randomisationprocedure
(p 1516)
Allocation concealment (selection bias) Unclear risk “According to block-stratified randomisa-
tion, participants were randomly assigned
to each of the two treatment groups” (p
1516)
Other major baseline imbalance Unclear risk The study appears to be free of sources of
bias related to major baseline imbalance
(Table 1; p 1517)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “At the pharmacy, containers and tubing
of IVIg or saline were wrapped in sealed
opaque bags. The active treatment and
placebowere administered intravenously in
identical settings and regime” (p 1516)
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Achiron 2004 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Each patient was evaluated by an exam-
ining neurologist who was unaware of the
patient’s treatment assignment. Changes
on neurological examination to determine
whether a new relapse had occurred were
based on the neurological examination per-
formedby two evaluatingneurologists both
unaware of treatment assignment” (p 1516)
Incomplete outcome data (attrition bias)
All outcomes
Low risk One participant in the treated group and
zero participants in the placebo group were
lost to follow-up (Fig. 1, p 1516)
Selective reporting (reporting bias) High risk Disability-worsening that was included as
a secondary outcome was not reported in
the results
ACISS 2010
Methods Cohort study. Austrian MS participating centres: 29. Participant recruitment started in September 2003 and termi-
nated in December 2005. Final participant follow-up visits in December 2007
Participants N = 296. Women 72%. Age, mean (sd): 32.5 (9.5) years. Participants with newly diagnosed CIS. The diagnosis of
a CIS was based on the presence of signs and symptoms compatible with MS without evidence for any other CNS
disorder which might have caused them (Miller 2008). Monofocal presentation 80% (optic neuritis 29%; spinal cord
syndrome 27%; brain stem 25%; other 19%). Multifocal presentation: 16%. EDSS , median (range): 2.0 (0-6). Brain
MRI, abnormal: 94% of participants. Oligoclonal antibodies in cerebrospinal fluid, positive: 82% of participants
Interventions Treatments for 163 participants who completed 2 years of observation were:
N = 49 treated with DMTs within 3 months of CIS onset (early treatment). INF-ß 1a intramuscular: 76%; INFß-
1a subcutaneous and INF-ß 1b subcutaneous: 12% each; glatiramer acetate: 16%; others: 4%
N = 59 treated with DMTs between 3-24 months of follow-up (delayed treatment). IFNs: 76%; glatiramer acetate
20%; others: 4%
N = 55 never treated up to 24 months of follow-up
Outcomes Proportion of participants who converted to CDMS. Number of relapses over 2 years. EDSS (median and range).
Quality of life assessed globally with a VAS, which ranged from 0 (worst) to 100 (best). It was recorded at baseline
and through the follow-up by the participant and the treating physician independently
Notes No analysis was done to reduce confounding. The study organisation and monitoring were supported by Biogen Idec
Austria
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BENEFIT 2006
Methods RCT, parallel-group. Recruitment period: February 2002-June 2003. Countries: 18 Eu-
ropean countries, Israel and Canada. Centres: 98
Participants N = 487. Women 71%; Age, mean (range): 31 years (18-45 years). Participants with a a
first neurological event suggestive of MS within 2 months after onset of the first event.
Presentation: monofocal 52% (optic neuritis 17%; spinal cord syndrome 16%; brain
stem or cerebellar syndrome 12%; other cerebral 7%), or multifocal 48%. They had at
least two clinically silent lesions on their T2-weighted brain MRI scan with a size of at
least 3 mm, at least one of which being ovoid, periventricular, or infratentorial
Interventions Interferon beta-1b (Betaseron) 250 µg subcutaneous every other day for 24 months (N=
305)
Placebo subcutaneous every other day for 24 months (N = 182)
Corticosteroid treatment of first relapse: 71%
Participants who converted to CDMS during the double-blind period were offered in-
terferon beta-1b 250 µg subcutaneously every other day for up to 5 years from randomi-
sation. (BENEFIT 2007 (3 years FU)) (p 390)
Outcomes Primary: time to conversion to CDMS represented by Kaplan-Meier estimates of the
cumulative percentage of participants with CDMS, defined by: 1) a relapse with clinical
evidence of at least one CNS lesion, and if the first presentation was monofocal distinct
from the lesion responsible for the CIS presentation, or 2) sustained progression by 1.5
points on the EDSS reaching a total EDSS score of 2.5 and confirmed at a consecutive
visit 3 months later (slightly modified Poser criteria). The validity of CDMS diagnoses
was confirmed by a central committee
Notes Funded by Schering AG. Four co-authors of Schering AG. Restriction description: any
manuscript/abstract related to the study had to be submitted for review to the sponsor
at least 90 days prior to publication (clinicalTrials.gov)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “A minimization procedure with an ele-
ment of chance was applied to minimize
imbalance of treatment groups for (se-
lected) factors with potential impact on the
risk of developing definite MS: steroid use
during the first clinical event; onset of the
first event as monofocal vs multifocal by
central assessment; number of T2 lesions
on the screening MRI” (p 1243)
Allocation concealment (selection bias) Low risk Central randomisation in a 5:3 ratio (p
1243)
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BENEFIT 2006 (Continued)
Other major baseline imbalance Low risk The study appears to be free of sources of
bias related tomajor baseline imbalance (ta-
ble 1; p 1244)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “After CDMS confirmation, all evalua-
tions foreseen per protocol for the month
24/end-of-study visit were performed. At
this end-of-study visit-without breaking
the randomisation code-participants were
given the option of participating in the
follow-up study with open-label interferon
beta-1b treatment” (p 1243). High risk of
un-blinding after shifting to open-label ac-
tive treatment during the randomised study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Participants were instructed to cover in-
jection sites during the examination by the
masked evaluation neurologist”. The diag-
nosis of CDMS had to be confirmed by a
central committee whose masking was not
reported (p 1243)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Proportions and reasons of incomplete out-
comedata did not differ substantially across
intervention groups. 437 (89.7%) of the
487 randomised participants completed
the study (271 (88.8%) of 305 allocated
to IFNB-1b and 166 (91.2%) of 182 al-
located to placebo). 34 (11.2%) IFNB-1b
participants did not complete the study:
13 did not receive IFNB-1b and were not
followed; 8 adverse event; 3 lost to fol-
low-up; 9 withdrawal by subject; 1 adverse
event, then subject’s withdrawal. 16 (8.8%)
placebo did not complete the study: 6 did
not receive placebo and were not followed;
2 lost to follow-up; 7withdrawal by subject;
1 fulfilled local definition and McDonald
criteria
Selective reporting (reporting bias) Low risk The study protocol was not available but it
is clear that the published reports included
all expected outcomes, including those that
were pre-specified
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BENEFIT 2007 (3 years FU)
Methods OLE study of the BENEFIT 2006 (placebo-controlled phase of 24 months). Centres:
97 of the original 98 BENEFIT study sites
Participants N = 418. Women 71%. Age, median: 30 years
Interventions N = 261/305 originally randomised to Interferon beta-1b 250 µg subcutaneous every
other day (early-treatment group). Active treatment exposure: 36 months
N = 157/182 originally randomised to placebo (delayed-treatment group). Active treat-
ment exposure: 12 months
Outcomes Time to CDMS and time to confirmed disability progression measured by EDSS scale
at 36 months. Annualised relapse rate
Notes Multivariate Cox regressions for time to CDMS and time to McDonald MS (steroid
use during the first clinical event, onset of disease (monofocal vs multifocal), age at
screening, sex, and number of T2 lesions and gadolinium-enhanced lesions at screening;
time to confirmed EDSS progression was adjusted (as preplanned) for T2-lesion volume
at screening)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No random assignment to the OLE groups
Allocation concealment (selection bias) High risk No allocation concealment to the OLE
groups
Other major baseline imbalance Low risk Clinical characteristics were similar be-
tween the two groups
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unblinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Unblinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk 18% and 21% of early and delayed treat-
ment groups, respectively, dropped out.
Proportions and reasons of missing partici-
pants did not differ substantially across in-
tervention groups
Selective reporting (reporting bias) High risk Serious adverse events not reported
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BENEFIT 2009 (5 years FU)
Methods OLE study of the BENEFIT 2006 (placebo-controlled phase of 24 months). Centres:
97 of the original 98 BENEFIT study sites
Participants N = 418. Women 71%. Age, median: 30 years
Interventions N = 261/305 originally randomised to Interferon beta-1b 250 µg subcutaneous every
other day (early-treatment group). Active treatment exposure: 60 months
N = 157/182 originally randomised to placebo (delayed-treatment group). Active treat-
ment exposure: 36 months
Outcomes Time to CDMS and time to confirmed disability progression measured by EDSS scale
at 60 months. Annualised relapse rate and proportions with relapses
Notes Adjusted Cox proportional hazards regression for time to conversion (steroid use during
the first clinical event, onset of disease (monofocal vs multifocal), age, sex, and number
of T2 lesions and gadolinium-enhancing lesions at screening)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No random assignment to the OLE groups
Allocation concealment (selection bias) High risk No allocation concealment to the OLE
groups
Other major baseline imbalance Unclear risk Insufficient information
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unblinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Unblinding
Incomplete outcome data (attrition bias)
All outcomes
High risk 23% and 32% of early and delayed treat-
ment groups, respectively, dropped out.
Proportions and reasons for missing par-
ticipants differed substantially across inter-
vention groups
Selective reporting (reporting bias) High risk Treatment discontinuation for adverse
events not reported
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BENEFIT 2014 (8.7 years FU)
Methods OLE study of the BENEFIT 2006 (placebo-controlled phase of 24 months). Centres:
72 of the original 98 BENEFIT study sites
Participants N = 284 recruited from 72 of the 97 initial centres in the BENEFIT RCT. Women 71%.
Age, median: 30 years
Interventions N = 178/305 originally randomised to Interferon beta-1b 250 µg subcutaneous every
other day (early-treatment group). Active treatment exposure: 60 months
N = 106/182 originally randomised to placebo (delayed-treatment group). Active treat-
ment exposure: 36 months
Outcomes Time to CDMS and time to confirmed disability progression measured by EDSS scale
at 8.7 years. Annualised relapse rate
Notes Proportional hazards regression (covariates: randomised treatment, steroid use during
the first clinical event, type of disease onset and categorised number of T2 lesions on
BENEFITscreening MRI)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No random assignment to the OLE groups
Allocation concealment (selection bias) High risk No allocation concealment to the OLE
groups
Other major baseline imbalance Unclear risk Insufficient information
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unblinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Unblinding
Incomplete outcome data (attrition bias)
All outcomes
High risk 48.5% and 44.5% of early and delayed
treatment groups, respectively, dropped
out. Proportions and reasons for missing
participants differed substantially across in-
tervention groups
Selective reporting (reporting bias) High risk Treatment discontinuation for adverse
events not reported
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BENEFIT 2016 (11 years FU)
Methods Following theOLE study, a prospective, comprehensive, 11-year, cross-sectional reassess-
ment of the BENEFIT 2006 (placebo-controlled phase of 24 months). Centres: 66 of
the original 98 BENEFIT study sites
Participants N = 278 recruited from 66 of the 97 initial centres in the BENEFIT RCT. Women 70%.
Age, median: 30 years
Interventions N = 167/305 originally randomised to Interferon beta-1b 250 µg subcutaneous every
other day (early-treatment group). Active treatment exposure: 60 months
N = 111/182 originally randomised to placebo (delayed-treatment group). Active treat-
ment exposure: 36 months
Outcomes Time to CDMS and time to confirmed disability progression measured by EDSS scale
at 11 years. Annualised relapse rate
Notes Proportional hazards regression for time-to-event outcomes and generalised linear regres-
sion models. Steroid use during first event (yes or no), multifocal or monofocal onset of
disease, and number of T2 lesions at screening (2-4, 5-8, or≥9) included as the standard
set of covariates. An extended set of covariates that included number of gadolinium-
enhancing (Gd1) lesions at screening, age, and sex in addition to the standard covariates
was used for analysis of time to CDMS, time to first relapse, and ARR
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No random assignment to the OLE groups
Allocation concealment (selection bias) High risk No allocation concealment to the OLE
groups
Other major baseline imbalance Unclear risk Insufficient information
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unblinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Unblinding
Incomplete outcome data (attrition bias)
All outcomes
High risk 45% and 39% of early and delayed treat-
ment groups, respectively, dropped out.
Proportions and reasons for missing par-
ticipants differed substantially across inter-
vention groups
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BENEFIT 2016 (11 years FU) (Continued)
Selective reporting (reporting bias) High risk Treatment discontinuation for adverse
events not reported
CHAMPS 2000
Methods RCT, parallel-group. Recruitment period: April 1996-March 2000. Countries: 2 (USA
and Canada). Centres: 50
Participants N = 383. Women 75%. Age, mean (range): 33 years (18-50 years). Participants with a
first isolated, well-defined neurologic event no more than 27 days before randomisation.
Monofocal presentation: 70% (optic neuritis 50%; spinal cord syndrome 22%; brain
stem or cerebellar syndrome 28%). They had 2 or more clinically silent lesions of the
brain that were at least 3 mm in diameter on MRI scans (at least 1 lesion had to be
periventricular or ovoid)
Interventions Interferon beta-1a (Avonex) 30 µg intramuscular once a week for 18 months (N = 193)
Placebo intramuscular once a week for 18 months (N = 190)
All participants (100%) received corticosteroid treatment (18 days)
Acetaminophen (paracetamol) 650 mg before and after each injection during the first 6
months of treatment
Outcomes Primary: conversion to CDMS as defined by: 1) a new clinical abnormality consistent
with the participant’s report of neurological or visual symptom distinct from that of the
initial episode at study entry or: 2) worsening by 1.5 points on the EDSS confirmed at
a consecutive visit 3 months later (slightly modified Poser criteria)
Notes Funded by Biogen. Stopped after 18-month interim analysis
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “To assign participants randomly in ap-
proximately equal numbers to the two
treatment groups, we used a minimization
procedure to minimize imbalance of treat-
ment groups for (selected) factors the num-
ber of lesions on T2-weighted MRI scans
and the type of initial clinical event” (p899)
Allocation concealment (selection bias) Unclear risk No information
Other major baseline imbalance Low risk The study appears to be free of sources of
bias related to major baseline imbalance
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unclear risk of unblinding because it is un-
clear if participants could have shifted to ac-
tive treatment during the randomised study
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CHAMPS 2000 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Each patient was examined by a treat-
ing and an examining neurologist, both of
whom were unaware of the patient’s treat-
ment assignment (p 899). Clinical out-
comes were confirmed by a central end-
point committee whose members were un-
aware of the participants’ treatment assign-
ments” (p 899)
Incomplete outcome data (attrition bias)
All outcomes
High risk Truncated. The study period was planned
to be 3 years. It was stopped early after
18-month interim analysis of efficacy. 177
participants (46% of the randomised) (80
treated and 97 placebo) had completed the
study. At 3 years, 30withdrawals + 83 inter-
rupted = 113 (58.5%) in interferon group;
27 withdrawals + 66 interrupted = 93 (48.
9%) in placebo group. (Fig. 1; p 902)
Selective reporting (reporting bias) Low risk The study protocol was not available but
the published reports included all expected
outcomes, including those that were pre-
specified
CHAMPS 2006 (5 years FU)
Methods OLE study of the CHAMPS 2000 (placebo-controlled phase of 36 months) Centres: 32
of the original 50 CHAMPS study sites
Participants N = 203 recruited from 32 of the 50 initial centres in the CHAMPS trial. Women 77%
(early treatment), 74% delayed treatment. Age, mean: 35 years
Interventions N = 100/193 originally randomised to interferon beta-1a (Avonex) 30 µg intramuscular
once a week (early-treatment group). Active treatment exposure: 60 months
N = 103/190 originally randomised to placebo (delayed-treatment group). Active treat-
ment exposure: 24 months
Outcomes Time to CDMS and time to confirmed disability progression measured by EDSS scale
at 60 months. Annualised relapse rate
Notes Multivariate model was used to adjust for recipient age, clinical centre, baseline brain
MRI T2 lesion volume (log transformation), and the number of Gd lesions at baseline.
Effect modification related to these factors was assessed with interaction terms in the
model. Possible violations of the proportional hazards assumption were checked using
time-dependent variables
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CHAMPS 2006 (5 years FU) (Continued)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No random assignment to the OLE groups
Allocation concealment (selection bias) High risk No allocation concealment to the OLE
groups
Other major baseline imbalance Low risk Demographic and clinical characteristics
were similar between the 2 groups
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unblinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Unblinding
Incomplete outcome data (attrition bias)
All outcomes
High risk 50% and 51% of early and delayed treat-
ment groups, respectively, dropped out.
Proportions and reasons for missing par-
ticipants differed substantially across inter-
vention groups
Selective reporting (reporting bias) High risk Treatment discontinuation for adverse
events and serious adverse events not re-
ported
CHAMPS 2012 (10 years FU)
Methods OLE study of the CHAMPS 2000 (placebo-controlled phase of 36 months). Centres:
24 of the original 50 CHAMPS study sites
Participants N = 155 recruited from 24 of the 50 initial centres in the CHAMPS trial. Women 74%
(early treatment), 72% delayed treatment. Age, mean: 35 years
Interventions N = 81/193 originally randomised to interferon beta-1a (Avonex) 30 µg intramuscular
once a week (early-treatment group). Active treatment exposure: 120 months
N = 74/190 originally randomised to placebo (delayed-treatment group). Active treat-
ment exposure: 84 months
Outcomes Time to CDMS and time to confirmed disability progression measured by EDSS scale
at 60 months. Annualised relapse rate
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CHAMPS 2012 (10 years FU) (Continued)
Notes Multivariate model was used to adjust for recipient age, clinical centre, baseline brain
MRI T2 lesion volume (log transformation), and the number of Gd lesions at baseline.
Effect modification related to these factors was assessed with interaction terms in the
model. Possible violations of the proportional hazards assumption were checked using
time-dependent variables
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No random assignment to the OLE groups
Allocation concealment (selection bias) High risk No allocation concealment to the OLE
groups
Other major baseline imbalance Unclear risk Insufficient information about clinical
characteristics of participants
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unblinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Unblinding
Incomplete outcome data (attrition bias)
All outcomes
High risk 65% and 69% of early and delayed treat-
ment groups, respectively, dropped out.
Proportions and reasons for missing par-
ticipants differed substantially across inter-
vention groups
Selective reporting (reporting bias) High risk Treatment discontinuation for adverse
events not reported
ETOMS 2001
Methods RCT, parallel-group. Recruitment period: August 1995-July 1997. 14 countries in Eu-
rope. Centres: 57
Participants N = 309. Women 64%. Age, mean (range): 28 years (18-40 years)
Participants with a first neurological episode suggesting multiple sclerosis in the previous
3 months. Monofocal (61%) or multifocal presentation. They had positive brain MRI
for at least 4 white-matter lesions on the T2-weighted scans, or presence of at least 3
white-matter lesions, if at least one was infratentorial or enhancing after gadolinium
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ETOMS 2001 (Continued)
Interventions Interferon beta-1a (Rebif ) 22 µg subcutaneous once a week for 24 months (N = 154)
Placebo subcutaneous once a week for 24 months (N = 155)
Steroid use at first clinical demyelinating event: 70%
After the conversion to CDMS, the investigator discussed with the participant the pos-
sibility of starting open-label treatment with interferon beta-1a once weekly until the
completion of the trial (p 1577)
Outcomes Primary: conversion to CDMS defined according to Poser diagnostic criteria
Notes Funded by Serono. COI of authors not reported
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The treatment was assigned according to
a computer-generated randomisation list
stratified by centre” (p 1577)
Allocation concealment (selection bias) Unclear risk No information
Other major baseline imbalance Low risk The study appears to be free of sources of
bias related to major baseline imbalance
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “After the occurrence of the second exac-
erbation, as stipulated in the protocol, the
investigator discussed with the patient the
possibility of starting open-label treatment
with interferon beta-1a once weekly until
the completion of the trial”. (p 1577) High
risk of unblinding after shifting to open-la-
bel active treatment during the randomised
study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “At each study site, a treating physician was
responsible for the overall management of
the patient, including safety monitoring.
An evaluating physician was responsible
for all scheduled neurological examinations
and exacerbation follow-up. Two members
of the steering committee reviewed the doc-
umentation of all exacerbations and, by
consensus, classified them as confirmed or
unconfirmed” (p 1577)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Proportions and reasons of incomplete out-
comedata did not differ substantially across
intervention groups. 141 (91.6%) of 154
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ETOMS 2001 (Continued)
participants in Interferon beta-1a and 137
(88.4%) of 155 participants in the placebo
group completed the study
Selective reporting (reporting bias) Low risk The study protocol is available and all of
the study’s pre-specified (primary and sec-
ondary) outcomes have been reported
GERONIMUS 2013
Methods Prospective cohort study. Regione Emilia Romagna, Italy. MS participating centres: 22. Recruitment of participants
from December 2004-June 2007. Censoring date: 31 March 2010
Participants N=168.Women69%.Age,mean (sd): 33.0 (8.0) years. Participantswith first symptom suggestive of an inflammatory
demyelinating disorder of the central nervous system in the preceding 6 months. Monofocal presentation 73% (optic
neuritis 29%; brain stem/cerebellar 21%; cerebral or spinal 23%). Multifocal presentation: 27%. EDSS, median
(range): 1.0 (0-6.5). Participants with MRI positive for ≥ 3 Barkhof criteria: 60% of participants. Oligoclonal
antibodies in cerebrospinal fluid, positive: 68% of participants
Interventions N = 31 (18%) and N = 51 (30%) of participants were treated with disease-modifying drugs before or after conversion
to CDMS. N = 86 not treated
N = 67 interferon; N = 9 glatiramer acetate; N =3 intravenous immunoglobulin; N =2 azathioprine; N = 1 mitox-
antrone
N = 18 participants underwent at least one other treatment: natalizumab (10); glatiramer acetate (5); mitoxantrone
(3); azathioprine (2); plasma exchange (1)
Outcomes CDMS according to Poser criteria. Follow-up 2 and 4 years
Notes Multivariate analysis was done using the Cox proportional-hazard regression model. Functional systems at onset were
categorised as afferent (visual or sensitive or both), efferent (any of the others) or combined (afferent and efferent)
; Barkhof criteria were dichotomised as C3 of 4 (positive) versus B2 of 4 (negative). All the variables statistically
significant in the univariate analysis for conversion to MS according to either McDonald criteria or CDMS criteria
were simultaneously entered in the multivariate model, except the number of T2 lesions and GD positive lesions
that are already included in Barkhof criteria. This study was supported with an unconditional grant by Biogen Idec
Motamed 2007
Methods RCT. Recruitment period: October 2002-March 2005. Country: Iran. One centre
Participants N = 25. Women 68%. Age, mean (range): 25 years (17-39 years)
Participants with a first, isolated optic neuritis (32%), spinal cord (28%), brain stem
(24%) or cerebellar (16%) syndrome, and which was confirmed on ophthalmologic or
neurologic examination
Mean EDSS: 1.74 (SD = 0.76)
MRI scan judged to be positive according to McDonald criteria (revision of 2005)
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Interventions N = 11: interferon beta-1a (Rebif ) 22 µg subcutaneous 3 times a week for 21 months
N = 14: no disease-modifying treatment
Outcomes Worsening of disability measured by Kurtzke Expanded Disability Status Scale (EDSS)
and numbers of new relapses during 21 months of follow-up
Notes Sponsor not reported. Potential conflicts of interest of authors not reported
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information
Allocation concealment (selection bias) Unclear risk No information
Other major baseline imbalance Unclear risk BaselineMRI findings imbalance. (Table 1;
p 346)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Absence of blinding. (p 348)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Absence of blinding. (p 348)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information
Selective reporting (reporting bias) Unclear risk No information
MSBASIS 2016
Methods Prospective cohort study (the MSBase Incident Study - MSBasis) from an international MSBase Registry. MSBasis
started in November 2004. Centres: 50. Countries: 22
Participants N=3296.Women70.5%.Age,median (IQR): 31.6 (25.3-39.3) years. Registry participantswith aCISwith symptom
onset less than 12 months from the enrolment date. Clinical presentation: optic pathways 22%; supratentorial 20.
5%; brainstem 21.5%; spinal cord syndrome 26%). EDSS, median (IQR): 2.0 (1-2.5). Abnormal T1 and T2 MRI
scans were recorded in 47% and 96% of participants, respectively. Oligoclonal antibodies in cerebrospinal fluid,
positive: 32% of participants
Interventions N = 910 (28%) participants were treated with intramuscular IFNβ-1a (42.7%), subcutaneous IFNβ-1a (33.8%),
IFNβ-1b (18.4%), or glatiramer acetate (13.7%)
N = 2386 (72%) were not exposed to disease-modifying drugs during follow-up
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Outcomes Primary outcome: time to CDMS, i.e. individualised risk of clinical conversion to CDMS at 12 months. CDMS
defined as examination evidence of a symptomatic second neurological episode attributable to demyelination of
more than 24 hs’ duration and more than 4 weeks from the initial attack (Poser criteria). N = 5378.70 person-years
contributed to outcome data
Notes All models presented were adjusted for country to control for any residual inter-country heterogeneity, for baseline
and time-varying factors
The MSBasis study was supported by Merck Serono, between 2004 and 2009
ORACLE 2014
Methods RCT, parallel-group. Recruitment period: October 2008-October 2010. Countries: 34
(Argentina (2), Austria (2), Belgium (4), Bosnia and Herzegovina (1), Bulgaria (9),
Canada (1), Croatia (2), CzechRepublic (6), Estonia (2), Finland (4), France (3), Georgia
(3), Germany (2), India (6), Italy (19), Korea (5), Lebanon (1), Macedonia (1), Norway
(2), Poland (9), Portugal (4), Romania (4), Russia (25), Serbia (3), Singapore (1), Spain
(2), Sweden (3), Taiwan (3), Thailand (1), Turkey (2), Ukraine (3), UnitedArabEmirates
(1), UK (1), USA (23). Centres: 160
Participants N = 617. Women 65%. Age, mean (range): 32 years (18-55 years). Presentation: mono-
focal 52%; multifocal 48%. Participants with a first clinical demyelinating event within
75 days before screening. They had an abnormal brain MRI consisting of at least two
clinically silent T2-weighted MRI lesions, at least one of which was ovoid, periventric-
ular, or infratentorial, of at least 3 mm in diameter
Interventions Cladribine cumulative dose: 3.5 mg/kg body weight oral for 22 months (N = 206)
Cladribine cumulative dose: 5.25 mg/kg body weight oral for 22 months (N = 205)
Placebo oral tablets (undefined) oral for 22 months (N = 206)
Corticosteroid treatment of first relapse: 66%
Participants who converted to CDMS during the double-blind period entered the open-
label maintenance period and were offered open-label treatment with subcutaneous
interferon beta-1a, 44 µg 3 times weekly. participants who did not convert to CDMS
were eligible to enter the long-term follow-up without study drug until conversion to
MS according to the 2005 McDonald criteria, when they were treated with open-label
cladribine 3.5 mg/kg under the original design, or with subcutaneous interferon beta-
1a 44 µg three times weekly after the protocol amendment due to the sponsor’s decision
to terminate development of oral cladribine. Participants converting to CDMS during
long-term follow-up received interferon beta-1a 44 µg 3 times weekly. (p 258)
Outcomes Primary: time to CDMS conversion represented by Kaplan-Meier estimates of the cu-
mulative percentage of participants with CDMS (time frame: baseline up to month 22)
defined according to Poser criteria, i.e. the occurrence of a second attack or a sustained
increase in the expanded disability status scale (EDSS) score
Secondary: 1) time to develop MS conversion according to the revised McDonald Cri-
teria (2005) represented by Kaplan-Meier estimates of the cumulative percentage of par-
ticipants with McDonald MS (time frame: baseline up to month 22); 2) number of
participants with adverse events and serious adverse events (time frame: baseline up to
month 22)
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Notes Funded by Merck Serono SA Geneva, a subsidiary of Merck KGaA, Darmstadt, Ger-
many. Early termination following the sponsor’s decision (October 2011) (p 258). The
study was designed by members of the steering committee and the sponsor. Data were
collected, analysed, and interpreted by the sponsor. All authors had access to the data
and contributed to data analysis and interpretation (p 261)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomisation was done using a central
web-based randomisation system and was
stratified by geographic region”. (p 258)
Allocation concealment (selection bias) Low risk A central web-based randomisation system.
(p 258)
Other major baseline imbalance Low risk The study appears to be free of sources of
bias related to major baseline imbalance
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Participants who converted to CDMS
during the double-blind period entered the
open-label maintenance period and were
offered open-label treatment with subcuta-
neous interferon beta-1a, 44µg three times
weekly”. (p 258) High risk of unblinding
after shifting to open-label active treatment
during the randomised study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Masking was maintained using a two-
physician model (both doctors were
masked). The treating physician super-
vised studymedication administration, and
recorded and treated adverse events andMS
relapses. The evaluating physician assessed
all neurological findings and relapses, and
was additionally masked to patient labo-
ratory data. For every patient, conversion
to CDMS required confirmation and ap-
proval by a sponsor-appointed, treatment-
blinded study adjudication committee”. (p
258)
Incomplete outcome data (attrition bias)
All outcomes
High risk Truncated. The study period was planned
to be 22 months. It was stopped early
following the sponsor’s decision to stop
the cladribine programme (Supplementary
web-appendix). 211 (34%) of 614 ran-
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domised participants (104 Cladribine 5.
25 mg/kg; 131 Cladribine 3.5 mg/kg; and
104 placebo) completed the study (Fig. 3;
p 262). The number excludes participants
who converted to CDMS during the dou-
ble-blindperiod, and therefore left the dou-
ble-blind period to enter the open-label
maintenance
Selective reporting (reporting bias) High risk In the original protocol, an analysis of dis-
ability-worsening was to be done in partic-
ipants who had converted to CDMS but,
owing to the early trial termination, the
sponsor decided before database lock, and
with an amended statistical analysis plan,
not to analyse time to disability-worsening.
(p 260)
Pakdaman 2007
Methods RCT, parallel-group. Recruitment period: February 2002-August 2005. Country: Iran.
Centres: 4
Participants N = 217. Women 68%. Age, range: 19-50 years. Participants with a first optic neuritis
(48%), spinal cord syndrome (24%), brain stem or cerebellar syndrome (22%) in the
previous 3 months confirmed by neurologic examination. They had an abnormal brain
MRI consisting of 2 or more clinically silent lesions that were at least 3 mm in diameter
and at least 1 had to be periventricular or ovoid
Interventions Interferon beta-1a (Avonex) 30 µg intramuscular once a week for 36 months (N = 104
included in analysis)
Placebo (unspecified) for 36 months (N = 98 included in analysis)
Outcomes Primary: time to conversion to CDMS as defined by the occurrence of a second exac-
erbation that was attributed to a part of central nervous system that differed from the
initial episode at study entry
Secondary: time to second exacerbation
Notes Sponsor not reported. Potential conflicts of interest of authors not reported
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information
Allocation concealment (selection bias) Unclear risk No information
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Other major baseline imbalance Low risk The study appears to be free of sources of
bias related to major baseline imbalance
(Table 1; p 430)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Insufficient information. Only “double
blind trial” is reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Of the 217 participants randomised, 202
(93%) completed the study; 104 received
interferon beta 1a and 98 received placebo.
Data on participants in whom CDMS did
not occur were censored on the date they
were last seen by the neurologist. (p 430)
Selective reporting (reporting bias) High risk Selective under-reporting of data: conver-
sion to CDMS was reported but with in-
adequate detail for the data
PRECISE 2009
Methods RCT, parallel-group. Recruitment period: January 2004-January 2006. 16 countries
worldwide, in 80 centres from the USA, Europe, Argentina, Australia, and New Zealand
Participants N = 481. Women 67%. Age, mean (range): 31 years (18-45 years). Monofocal presenta-
tion: 100%. Participants with one unifocal neurological event within 90 days after onset.
They had positive brain MRI for at least 2 cerebral lesions on the T2-weighted images
of at least 6 mm in diameter
Interventions Glatiramer acetate (Copaxone) 20 µg subcutaneous once a day for 36 months (N = 243)
Placebo subcutaneous once a day for 36 months (N = 238)
Steroid use at first clinical demyelinating event: 64%
Ibuprofen (400 mg) or paracetamol (acetaminophen) (1000 mg) prophylactically with
each injection during the first 3 months of treatment
All participants switched to active treatment with glatiramer acetate upon conversion to
CDMS. (p 1506)
Outcomes Primary: time to conversion to CDMS defined by: 1) a second event suggestive of MS
lasting at least 48 h duration or: 2) worsening by 1.5 points on the EDSS confirmed at
a consecutive visit 3 months later (slightly modified Poser criteria)
Notes Funded by TEVA. The sponsor was involved in the study design, conduct, monitoring,
data analysis, and writing of the report. The corresponding author had full access to all
the data and had final responsibility for the decision to submit for publication (p 1507)
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Restriction: should the investigator wish to publish the results of this study, he/she
agrees to provide Teva with a manuscript for review 60 days prior to submission for
publication. Teva retains the right to delete confidential information and to object to
suggest publication and/or its timing (at the Company’s sole discretion)
If Teva chooses to publish this study a copy will be provided to the investigator at least
30 days prior to the expected date of submission to the intended publisher (trial.gov)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The randomisation scheme was produced
by the sponsor of the study with a 1:1 as-
signment ratio. A SAS-based blocks with
block size of 4, stratified by centre was
used”. (p 1504)
Allocation concealment (selection bias) Unclear risk No information
Other major baseline imbalance Low risk The study appears to be free of sources of
bias related to major baseline imbalance.
(table 2; p 1506)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The criterion to enter the prospectively
planned open label study phase was either
a second relapse or the end of the dou-
ble-blind phase, whichever came first.High
risk of unblinding after shifting to open-la-
bel active treatment during the randomised
study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear risk for blinding of clinical out-
come assessment. “Treating and examin-
ing neurologists at the sites were masked
to MRI results during the study. The un-
masked statistician presented unmasked re-
sults to the Data Monitoring Committee,
as per their request” (p 1504)
Incomplete outcome data (attrition bias)
All outcomes
High risk Truncated. The study period was planned
to be 3 years. Based on the results of a
planned interim analysis of efficacy and
on the recommendations of the data mon-
itoring committee (unmasked), the trial
was stopped early and all participants were
switched to glatiramer acetate. At the time
of the interim analysis, 230 (47.8%) of
481 randomised participants completed
the study. 98 (40.3%) of 243 treated par-
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ticipants and 132 (55.5%) of 238 placebo
completed the study. Proportion and rea-
sons of incomplete data differed between
the groups. 39 (16.0%) of 243 participants
in the glatiramer group and 23 (8.8%)
of 238 in the placebo group discontinued
treatment early (table 1, p 1505) and the
proportion of termination because of ad-
verse events differed significantly between
the two treatment groups
Selective reporting (reporting bias) Low risk The study protocol was available and all of
the study’s pre-specified primary outcomes
were reported
PRECISE 2013 (5 years FU)
Methods OLE study of the PRECISE 2009 (placebo-controlled phase of 36 months). Centres:
80 of the original 80 PRECISE study sites
Participants N = 409. Women 69% and 65% in the early and delayed groups, respectively. Age,
median: 30 years
Interventions N = 198/243 originally randomised to glatiramer acetate (early-treatment group). Active
treatment exposure: 60 months
N = 211/238 originally randomised to placebo (delayed-treatment group). Active treat-
ment exposure: 24 months
Outcomes Time to CDMS and time to confirmed disability progression measured by EDSS scale at
60 months. Annualised relapse rate. Proportion of participants with relapses or disability
progression
Notes Risk of conversion to CDMS from a Cox’s proportional hazards model was assessed for
early- and delayed-treatment subgroups defined by demographics, characteristics of CIS
(gender, age, presenting syndrome, steroid treatment for the initial attack) and MRI
findings (disease dissemination and activity), at baseline
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No random assignment to the OLE groups
Allocation concealment (selection bias) High risk No allocation concealment to the OLE
groups
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Other major baseline imbalance Unclear risk Clinical characteristics were similar be-
tween the two groups
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unblinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Unblinding
Incomplete outcome data (attrition bias)
All outcomes
High risk 33% and 47% of early and delayed treat-
ment groups, respectively, dropped out.
Proportions and reasons for missing par-
ticipants differed substantially across inter-
vention groups
Selective reporting (reporting bias) Low risk Prespecified outcome were reported in-
cluding adverse events and serious adverse
events
REFLEX 2012
Methods RCT, parallel-group. Recruitment period: November 2006-August 2010. 28 countries
in Europe and Canada. Centres: 78
Participants N = 517. Women 64%. Age, mean (range): 31 years (18-50 years). Participants with a
single event suggestive ofMS within 60 days before study entry. Presentation: monofocal
54%; multifocal 46%. They had at least two clinically silent lesions of 3 mm or more
on T2-weighted brain MRI scan, at least one of which was ovoid, periventricular, or
infratentorial
Interventions Interferon beta-1a (Rebif ) 44 µg subcutaneous 3 times a week for 24 months (N = 171)
Interferon beta-1a (Rebif ) 44 µg subcutaneous once a week and placebo subcutaneous
2 times a week for 24 months (N = 175)
Placebo subcutaneous 3 times a week for 24 months (N = 171)
Steroid use at first clinical demyelinating event: 71%
Ibuprofen (400 mg) or paracetamol (acetaminophen) (1000 mg) prophylactically with
each injection during the first 3 months of treatment
On conversion to CDMS, participants were switched to open-label subcutaneous inter-
feron beta-1a at 44 µg 3 times a week until the end of the 24 months
Outcomes Primary: time to conversion to MS according to the McDonald Criteria (2005) to 24
months
Secondary: time to conversion to CDMS defined by either a second attack or a 3-month
sustained increase (≥ to 1.5 points) in EDSS score (slightly modified Poser criteria)
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Notes Funded byMerck Serono. The study was designed bymembers of the steering committee
and the sponsor. The sponsor collected the data, did the analysis, and was involved in the
interpretation of the data. The data were available to all authors, and they contributed
to the analysis and interpretation of the data. The steering committee was responsible
for the final decision to submit this report for publication
Restriction: sponsor has the right to publish any results communication in connection
with the study. The PI shall submit any communications including study results to the
sponsor for review 30 working days prior to communication submission. The sponsor
can request the PI to modify or delete any sponsor’s proprietary information. If the PI
refuses the modification, the submission shall be postponed for 60 days from PI refusal,
to provide the sponsor the opportunity to file a patent or seek legal remedies (trial.gov)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central randomisation. “Randomisation
was stratified according to baseline factors:
age (<30 years vs ≥30 years), steroid use
for first event (yes vs no), classification of
first event (monofocal vs multifocal), and
at least oneMRI gadolinium-enhancing le-
sion (yes vs no)”. (p 34)
Allocation concealment (selection bias) Low risk “The study centre dialled a centralised in-
teractive voice response system to randomly
assign participants in a 1:1:1 ratio” (p 34)
. “A treatment kit number, corresponding
to the randomisation group, was allocated
centrally to each patient for use only by that
individual”. (p 34)
Other major baseline imbalance Low risk The study appears to be free of sources of
bias related to major baseline imbalance.
(table 1; p 36)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “On conversion to CDMS, participants
were switched to open-label subcutaneous
interferon beta-1a at 44 µg three times a
week until the end of the 24 months”. (p
34) High risk of unblinding after shifting
to open-label active treatment during the
randomised study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “A two-physician (treating and assessing)
model was used to assist with study mask-
ing. The treating physician was responsi-
ble for supervision of study drug admin-
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istration and for recording adverse events
and safety assessments. The assessing physi-
cian was not involved in the care of study
participants and was exclusively responsi-
ble for all neurological assessments, begin-
ning with the pre-study assessment. Injec-
tion sites were covered before a patient saw
the assessing physician to maintain mask-
ing”. (p 34)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 448 (87%) of the 517 randomised partici-
pants had completed the study: 146 (85%)
of 171 participants in interferon beta-1a 44
µg 3 times a week; 156 (89%) of 175 par-
ticipants in interferon beta-1a 44 µg once
a week; 146 (85%) of 171 in placebo. Pro-
portion and reasons of withdrawn from
study did not differ between the groups: 26
(15.2%) of 171 participants in interferon
beta-1a 44 µg 3 times a week; 20 (11.4%)
of 175 participants in interferon beta-1a 44
µg once a week; and 26 (15.2) of 171 in
placebo
Selective reporting (reporting bias) Low risk The study protocol was available and all of
the study’s pre-specified (primary and sec-
ondary) outcomes were reported
REFLEX 2016 (3 and 5 years FU)
Methods OLE study of the REFLEX 2012 (placebo-controlled phase of 24 months). Centres: 70
of the original 78 REFLEX study sites
Participants N = 402. Women 61%, 62% and 62% in the 3 groups, respectively. Age, mean: 31.4
(SD 8.3) years
Interventions N = 127/171 originally randomised to sc IFN β-1a 44 mg tiw (early-treatment group).
Active treatment exposure: 60 months
N = 142/175 originally randomised to sc IFN β-1a 44 µg qw (early-treatment group).
Active treatment exposure: 60 months
N = 133/171 in the delayed-treatment arm (originally randomised to placebo). Active
treatment exposure: 36 months
Outcomes Time to CDMS conversion (defined in REFLEX 2012) from first randomisation to
month 36; time toCDMS tomonth 60 (secondary end point). Proportion of participants
remaining relapse-free; time to confirmed disability-worsening (increase of EDSS ≥ 1.
0 point, confirmed during a visit 6 months later) and EDSS change from baseline
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Notes Probabilities of CDMS conversion, McDonald MS conversion and EDSS progression
over time were determined for each treatment group in the form of cumulative incidence
curves estimated using the non-parametric Kaplan-Meier method
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No random assignment to theOLE groups
Allocation concealment (selection bias) High risk No allocation concealment to the OLE
groups
Other major baseline imbalance Unclear risk Insufficient information about clinical
characteristics of participants
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unblinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Unblinding
Incomplete outcome data (attrition bias)
All outcomes
High risk 30%, 25%, and 29% dropped out re-
spectively in early and delayed treatments
groups with different reasons. Not re-
ported reasons for discontinuation across
the groups
Selective reporting (reporting bias) Low risk All expected outcomes were reported
Tintore 2015
Methods Prospective cohort study. Study started in January 1995 and the database was locked on 15 March 2013
Participants N = 1015. Women 68%. Age, mean (SD): 31.1(8.2) years. Monocentric. Participants with CIS that was suggestive
of CNS demyelination and was not attributable to other diseases, with symptom onset within 3 months of the first
clinical evaluation. Clinical topography at onset: optic neuritis 37%; spinal cord syndrome 26%; brain stem 27%;
other 11%. EDSS , median (range): 2.0 (0-6). Brain MRI available for 94% of participants and abnormal in 69% of
them. Oligoclonal antibodies in cerebrospinal fluid available for 79% of participants and positive in 57% of them
N = 1058 enrolled
- N = 43 (4%) excluded for various reasons: previous attack (N = 7), age over 50 (N = 4), exceeded entry window (N
= 12), and alternative diagnosis (N = 20)
- N = 1015 included in analysis
- N = 7 (0.7%) died during follow-up: car accident (N = 1), myocardial infarction (N = 1), pancreatic cancer (N =
1), meningitis as a complication of septoplasty (N = 1), septic shock in a participant with severe disability (N = 1),
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cardiogenic shock of unknown origin (N = 1) and acute leukemia in a participant who received mitoxantrone (N =
1)
Interventions N = 388 (38.3%) of participants were on DMT at least once during follow-up (IFNs or glatiramer acetate)
N = 174 (45%) of participants were on DMTs prior to conversion to clinical definite MS (early treatment)
N = 214 (55%) of participants were on DMTs after conversion to CDMS (delayed treatment)
N = 376 (97%) of participants were on DMTs prior to reaching an EDSS score of 3.0
N = 281(75.3%) of 375 participants with 3-4 Barkhof criteria at baseline received DMT, 143 (51%) of those prior
CDMS (early treatment), and 273 (97%) prior to EDSS score of 3.0
The mean time to DMT was significantly shorter in the participants with CIS from 2002-2007 compared with those
from 1995-2001 (15.2 months SD = 21 versus 41.5 months, SD = 38, P < 0.001)
Outcomes CDMS and disability-worsening (reaching EDSS score 3.0). Clinical follow-up duration, mean (SD) (range): 81
(57) (0.3-220) months
The participants were evaluated on a regular basis (every 3-6 months or annually depending on each participant’s
characteristics). The participants who did not attend two consecutive follow-up visits were defined as ‘lost to follow-
up’
Notes Multivariate Cox proportional hazards regression analyses for the time to conversion to CDMS or McDonald.
Covariates including age, gender, clinical topography, oligoclonal bands, MRI criteria (Barkhof criteria and the
number of lesions) and DMT onset prior to the diagnosis of CDMS or McDonald 2005 multiple sclerosis criteria,
depending on the outcome, were considered. Possible interactions between age, gender, topographic characteristics,
the presence of oligoclonal bands, the number of lesions and DMT were also evaluated. DMT was used in these
models as a time-dependent variable to take into account the date of treatment onset
This work is independent of all the funding bodies, which have played no part in any of its stages
TOPIC 2014
Methods RCT, parallel-group. Recruitment period: February 2008-August 2012. 20 countries in
Europe, USA, Canada, and Australia. Centres: 112
Participants N = 618. Women 68%. Age, mean (range): 32 years (18-55 years). Presentation: mono-
focal 59%; multifocal 41%. Participants with a first acute or subacute optic neuritis,
spinal cord syndrome, brain stem or cerebellar syndrome occurring within 3 months
before randomisation. They had an abnormal brain MRI consisting of at least two T2-
weighted MRI lesions of at least 3 mm in diameter
Interventions Teriflunomide 14 mg oral capsule once daily for up to 25 months (N = 216)
Teriflunomide 7 mg oral capsule once daily for up to 25 months (N = 205)
Placebo oral capsule once daily for 25 months (N = 197)
Previous systemic corticosteroid treatment: 14%
Outcomes Primary: conversion to CDMS as defined by the occurrence of a second relapse (Poser
diagnostic criteria)
Secondary: time to relapse
Notes Funder Sanofi, Genzyme. Data were obtained by the investigators and were analysed
by the sponsor. Interpretation of the data was done by the sponsor and the authors. All
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authors had full access to, and take responsibility for, the veracity of study data
TOPIC was stopped on Aug 10, 2012, because the 2010 revisions of the MCDonald
diagnostic criteria enabled an earlier diagnosis of multiple sclerosis, in some cases at first
clinical event. Re-evaluation of the power calculation based on updated information from
the teriflunomide clinical programme, especially from the TOWER study, indicated that
sufficient power to detect a reduction in risk of relapse had already been achieved
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomisation was done centrally, by an
interactive voice recognition system that
generated an allocation sequence using
a permuted-block randomisation schedule
(block size of six) with stratification by
baselinemonofocal ormultifocal status”. (p
978)
Allocation concealment (selection bias) Low risk “An independent company (ClinPhone,
Perceptive Informatics, Nottingham, UK)
ran and maintained the interactive voice
recognition system for the duration of the
study, under the responsibility of the study
funder. After a screening phase (up to 4
weeks), investigators called the interactive
voice recognition system to receive a ran-
dom, masked treatment assignment for
each patient”. (p 978)
Other major baseline imbalance Low risk The study appears to be free of sources of
bias related to major baseline imbalance.
(table 1; p 980)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants who had a relapse which de-
fined CDMS, and had been treated for at
least 24 weeks, could also enter the OLE
study. (p 978) High risk of unblinding af-
ter shifting to open-label active treatment
during the randomised study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “A treating neurologist at each site as-
sessed participant eligibility, supervised
study drug administration, and did the sa-
fety assessments. An independent examin-
ing neurologist was responsible for all func-
tional system and EDSS assessments. Re-
lapses indicating CDMS were confirmed
by the treating neurologist based on the ex-
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amining neurologist’s EDSS assessment” (p
979)
Incomplete outcome data (attrition bias)
All outcomes
High risk At least 41%and 45% in the treated groups
and 40% in the placebo group were lost to
follow-up (Fig. 2; p 980)
Selective reporting (reporting bias) Low risk The study protocol is not available, how-
ever the published reports included all ex-
pected outcomes
CDMS: clinically definite multiple sclerosis; CIS: clinically isolated syndrome;CNS: central nervous system;DMT: disease-modifying
treatment; EDSS: Expanded Disability Status Scale; h: hour; IFN: interferon; MRI: magnetic resonance imaging; MS: multiple
sclerosis; N: number; OLE: open-label extension; VAS: visual analogue scale
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
BENEFIT 2007 Subanalysis of BENEFIT 2006 to evaluate prognostic effect of MRI at baseline on conversion
to CDMS
BENEFIT 2008 Subanalysis of BENEFIT 2006 trial to evaluate predictive effect of treatment in subgroups of
participants
BENEFIT 2011 Subanalysis of BENEFIT 2006 trial to evaluate the frequency and consequences of neutralizing
antibodies in subgroups of participants
BENEFIT 2012 Subanalysis of BENEFIT 2006 trial and open label extension (5 years) study to evaluate cognitive
performance in subgroups of participants
BENEFIT 2014a Subanalysis of BENEFIT 2006 trial to evaluate effect of Vitamin-D on conversion to CDMS
BENEFIT 2014b Reanalysis of BENEFIT 2006 trial and OLE (5 years) study (BENEFIT 2009 (5 years FU)) to
evaluate predictive effect of treatment on persisting T1 hypointensities on MRI
CHAMPIONS 2015 Reanalysis of CHAMPS 2000 trial and OLE (10 years) study (CHAMPS 2012 (10 years FU))
to compare the 10-year disease progression between subgroups of participants with different
baseline MRI characteristics (low and higher T2 lesion counts)
CHAMPS 2001 Subanalysis of CHAMPS 2000 trial in participants with a first clinical attack of optic neuritis
CHAMPS 2002a Subanalysis of CHAMPS 2000 trial in participants allocated to placebo group
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(Continued)
CHAMPS 2002b Subanalysis of CHAMPS 2000 trial to evaluate predictive effect of baseline characteristics on
conversion to CDMS
CHAMPS 2002c Subanalysis ofCHAMPS 2000 trial to evaluate prognostic effect ofMRI at baseline on conversion
to CDMS
CHAMPS 2003 Subanalysis of CHAMPS 2000 trial to evaluate predictive effect of treatment in subgroups of
high risk participants
CHAMPS 2009 Reanalysis of CHAMPS 2000 trial to evaluate predictive effect of treatment in subgroups of
participants with different baseline risk of disease progression
Curkendall 2011 Outcomes were not measured. A retrospective study using insurance claims data (2000-2008) of
participants with a first clinical attack suggestive of MS. The objective of the study was to assess
health care utilisation and expenditures associated with treating participants early with disease-
modifying drugs rather than delaying until participants met the full diagnostic criteria of MS
ETOMS 2003 Subanalysis of ETOMS 2001 trial to evaluate prognostic effect of MRI at baseline on conversion
to CDMS
Filippi 2004 Subanalysis of ETOMS 2001 trial to evaluate prognostic effect of MRI at baseline on conversion
to CDMS
Kuhle 2015 Cohort study. No treatment with disease-modifying drugs
Lazzaro 2009 An open cohorts epidemiological model based on demographics of participants enrolled in
the BENEFIT 2006 trial. The model arbitrarily started with 2000 CIS participants diagnosed
according to Mc Donald criteria, i.e. MS
Meyniel 2012 Prospective cohort study. N = 125 (10%) participants initially treated with disease-modifying
drugs at the first clinical attack suggestive of MS were not reported separately from participants
(1094; 88%)who converted to relapsing-remittingMS at the time of their first disease-modifying
drugs commencement
Moraal 2009 Reanalysis of CHAMPS 2000 trial to assess the prognostic value of baseline MRI for conversion
to CDMS over 3 years and the predictive effect of the intervention
Mowry 2009 Prospective cohort study. N = 9 (9%) participants who began disease-modifying drugs within 1
year of their first clinical attack suggestive of MS were not reported separately from participants
(96; 91%) who converted to relapsing-remitting MS at the time of their first disease-modifying
drugs commencement
MSBASIS 2015 Prospective cohort study, a sub-study of theMSBaseRegistry (an international online database on
MS). N = 252 (19%) participants who began disease-modifying drugs at their first clinical attack
suggestive of MS were not reported separately from participants (1087; 81%) who converted to
relapsing-remitting MS at the time of their first disease-modifying drugs commencement
69Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
REFLEX 2014a Subanalysis of REFLEX 2012 trial to evaluate predictive effect of participants’ baseline charac-
teristics
REFLEX 2014b Subanalysis of REFLEX 2012 trial to evaluate prognostic effect of MRI at baseline on conversion
to CDMS
SWISS COHORT STUDY 2013 Cohort Study. N = 54 (10%) participants initially treated with disease-modifying drugs at their
first clinical attack suggestive of MS were not reported separately from participants (492; 90%)
who converted to relapsing-remitting MS at the time of their first disease-modifying drugs
commencement
SWISS COHORT STUDY 2016 Cohort study. Outcomes were not measured
CDMS: clinically definite multiple sclerosis; CIS: clinically isolated syndrome; MRI: magnetic resonance imaging; MS: multiple
sclerosis; OLE: open-label extension
Characteristics of ongoing studies [ordered by study ID]
NCT01013350
Trial name or title Prospective observational long-term safety registry of multiple sclerosis patients who have participated in
cladribine clinical trials (PREMIERE)
Methods Observational study
Participants Estimated enrolment: 1190. Subjects with MS and had already participated in sponsor oral cladribine clinical
development trials
Interventions Cladribine
Outcomes • Number of participants with serious adverse drug reactions (SADRs)
• Time to resolution of lymphopenia, among registry participants with persistent lymphopenia
• Number of participants with all adverse events (adverse events)
Time frame: up to the end of the registry, which is planned for 2018, or 8 years after the participant’s first
enrolment into a cladribine clinical trial, whichever occurs first
Starting date November 2009
Contact information US Medical Information
Notes ClinicalTrials.gov identifier: NCT01013350
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NCT01371071
Trial name or title Cohort study of clinically isolated syndrome and early multiple sclerosis (CIS-COHORT)
Methods Prospective cohort
Participants Estimated enrolment: 200 participants with CIS within the last 6 months or diagnosis of MS within the last
2 years
Interventions Immunomodulatory therapy
Outcomes Primary: time (in days) until relapse during the observation period of 4 years
Starting date January 2011
Contact information Prof. Friedemann Paul friedemann.paul@charite.de; Dr. Klemens Ruprecht klemens.ruprecht@charite.de
Notes ClinicalTrials.gov identifier: NCT01371071
CIS: clinically isolated syndrome; MS: multiple sclerosis
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D A T A A N D A N A L Y S E S
Comparison 1. Active intervention versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Occurrence of at least one serious
adverse event over 24 months
7 3385 Odds Ratio (M-H, Random, 95% CI) 0.78 [0.60, 1.03]
1.1 Interferon beta-1b
(Betaseron) versus placebo
1 468 Odds Ratio (M-H, Random, 95% CI) 1.00 [0.48, 2.11]
1.2 Interferon beta-1a
(Avonex) versus placebo
1 383 Odds Ratio (M-H, Random, 95% CI) 0.60 [0.28, 1.27]
1.3 Interferon beta-1a (Rebif )
versus placebo
2 823 Odds Ratio (M-H, Random, 95% CI) 0.72 [0.35, 1.46]
1.4 Glatiramer acetate versus
placebo
1 481 Odds Ratio (M-H, Random, 95% CI) 0.55 [0.25, 1.17]
1.5 Teriflunomide versus
placebo
1 614 Odds Ratio (M-H, Random, 95% CI) 1.06 [0.59, 1.89]
1.6 Cladribine versus placebo 1 616 Odds Ratio (M-H, Random, 95% CI) 0.77 [0.43, 1.37]
2 Occurrence of at least one serious
adverse event over 36 months
1 Odds Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Interferon beta-1a
(Avonex) versus placebo
1 202 Odds Ratio (M-H, Random, 95% CI) 1.23 [0.44, 3.45]
3 Withdrawing from the study or
discontinuing the drug due to
adverse events over 24 months
5 2693 Odds Ratio (M-H, Random, 95% CI) 2.43 [0.91, 6.49]
3.1 Interferon beta-1b
(Betaseron) versus placebo
1 468 Odds Ratio (M-H, Random, 95% CI) 21.54 [2.92, 159.08]
3.2 Interferon beta-1a (Rebif )
versus placebo
1 514 Odds Ratio (M-H, Random, 95% CI) 0.73 [0.26, 2.10]
3.3 Glatiramer acetate versus
placebo
1 481 Odds Ratio (M-H, Random, 95% CI) 3.58 [1.16, 11.03]
3.4 Teriflunomide versus
placebo
1 614 Odds Ratio (M-H, Random, 95% CI) 1.02 [0.58, 1.81]
3.5 Cladribine versus placebo 1 616 Odds Ratio (M-H, Random, 95% CI) 4.13 [1.44, 11.87]
4 Withdrawing from the study or
discontinuing the drug due to
adverse events over 12 months
1 Odds Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Interferon beta-1a
(Avonex) versus placebo
1 383 Odds Ratio (M-H, Random, 95% CI) 0.14 [0.02, 1.12]
5 Time to conversion to CDMS
over 24 months
9 Hazard Ratio (Random, 95% CI) 0.53 [0.47, 0.60]
5.1 Interferon beta-1b
(Betaseron) versus placebo
1 Hazard Ratio (Random, 95% CI) 0.50 [0.36, 0.69]
5.2 Interferon beta-1a
(Avonex) versus placebo
1 Hazard Ratio (Random, 95% CI) 0.56 [0.38, 0.83]
5.3 Interferon beta-1a (Rebif )
versus placebo
2 Hazard Ratio (Random, 95% CI) 0.57 [0.43, 0.77]
72Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
5.4 Glatiramer acetate versus
placebo
1 Hazard Ratio (Random, 95% CI) 0.55 [0.40, 0.76]
5.5 Teriflunomide versus
placebo
1 Hazard Ratio (Random, 95% CI) 0.57 [0.38, 0.86]
5.6 Cladribine versus placebo 1 Hazard Ratio (Random, 95% CI) 0.38 [0.25, 0.58]
5.7 Any DMD vs no
treatment
2 Hazard Ratio (Random, 95% CI) 0.48 [0.30, 0.78]
6 Time to conversion to CDMS
over 12 months
1 Hazard Ratio (Random, 95% CI) Subtotals only
6.1 Immunoglobulins versus
placebo
1 Hazard Ratio (Random, 95% CI) 0.36 [0.15, 0.86]
7 Withdrawing from the study or
discontinuing the drug for any
reason over 24 months
6 2931 Odds Ratio (M-H, Random, 95% CI) 1.00 [0.61, 1.62]
7.1 Interferon beta-1b
(Betaseron) versus placebo
1 487 Odds Ratio (M-H, Random, 95% CI) 1.50 [0.95, 2.35]
7.2 Interferon beta-1a
(Avonex) versus placebo
1 383 Odds Ratio (M-H, Random, 95% CI) 1.09 [0.65, 1.81]
7.3 Interferon beta-1a (Rebif )
versus placebo
2 826 Odds Ratio (M-H, Random, 95% CI) 0.52 [0.18, 1.44]
7.4 Teriflunomide versus
placebo
1 618 Odds Ratio (M-H, Random, 95% CI) 0.87 [0.59, 1.27]
7.5 Cladribine versus placebo 1 617 Odds Ratio (M-H, Random, 95% CI) 2.30 [1.49, 3.56]
8 Withdrawing from the study or
discontinuing the drug for any
reason over 12 months
1 Odds Ratio (M-H, Random, 95% CI) Subtotals only
8.1 Immunoglobulins versus
placebo
1 91 Odds Ratio (M-H, Random, 95% CI) 2.15 [0.37, 12.35]
Comparison 2. Early versus delayed treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Time to conversion to CDMS at
different follow-up years
10 Hazard Ratio (Random, 95% CI) Subtotals only
1.1 2-4 years’ follow-up 5 Hazard Ratio (Random, 95% CI) 0.62 [0.48, 0.81]
1.2 5 years’ follow-up 4 Hazard Ratio (Random, 95% CI) 0.62 [0.53, 0.73]
1.3 8.7-10 years’ follow-up 2 Hazard Ratio (Random, 95% CI) 0.65 [0.54, 0.79]
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Analysis 1.1. Comparison 1 Active intervention versus placebo, Outcome 1 Occurrence of at least one
serious adverse event over 24 months.
Review: Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis
Comparison: 1 Active intervention versus placebo
Outcome: 1 Occurrence of at least one serious adverse event over 24 months
Study or subgroup Experimental Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Interferon beta-1b (Betaseron) versus placebo
BENEFIT 2006 20/292 12/176 13.4 % 1.00 [ 0.48, 2.11 ]
Subtotal (95% CI) 292 176 13.4 % 1.00 [ 0.48, 2.11 ]
Total events: 20 (Experimental), 12 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
2 Interferon beta-1a (Avonex) versus placebo
CHAMPS 2000 12/193 19/190 13.0 % 0.60 [ 0.28, 1.27 ]
Subtotal (95% CI) 193 190 13.0 % 0.60 [ 0.28, 1.27 ]
Total events: 12 (Experimental), 19 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.35 (P = 0.18)
3 Interferon beta-1a (Rebif) versus placebo
ETOMS 2001 6/154 5/155 5.1 % 1.22 [ 0.36, 4.07 ]
REFLEX 2012 14/344 12/170 11.7 % 0.56 [ 0.25, 1.24 ]
Subtotal (95% CI) 498 325 16.7 % 0.72 [ 0.35, 1.46 ]
Total events: 20 (Experimental), 17 (Control)
Heterogeneity: Tau2 = 0.03; Chi2 = 1.11, df = 1 (P = 0.29); I2 =10%
Test for overall effect: Z = 0.91 (P = 0.36)
4 Glatiramer acetate versus placebo
PRECISE 2009 11/243 19/238 12.6 % 0.55 [ 0.25, 1.17 ]
Subtotal (95% CI) 243 238 12.6 % 0.55 [ 0.25, 1.17 ]
Total events: 11 (Experimental), 19 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.55 (P = 0.12)
5 Teriflunomide versus placebo
TOPIC 2014 42/423 18/191 21.9 % 1.06 [ 0.59, 1.89 ]
Subtotal (95% CI) 423 191 21.9 % 1.06 [ 0.59, 1.89 ]
Total events: 42 (Experimental), 18 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.85)
6 Cladribine versus placebo
0.01 0.1 1 10 100
Favours experimental Favours control
(Continued . . . )
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(. . . Continued)
Study or subgroup Experimental Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
ORACLE 2014 33/410 21/206 22.3 % 0.77 [ 0.43, 1.37 ]
Subtotal (95% CI) 410 206 22.3 % 0.77 [ 0.43, 1.37 ]
Total events: 33 (Experimental), 21 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.89 (P = 0.38)
Total (95% CI) 2059 1326 100.0 % 0.78 [ 0.60, 1.03 ]
Total events: 138 (Experimental), 106 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.03, df = 6 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 1.78 (P = 0.075)
Test for subgroup differences: Chi2 = 2.89, df = 5 (P = 0.72), I2 =0.0%
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 1.2. Comparison 1 Active intervention versus placebo, Outcome 2 Occurrence of at least one
serious adverse event over 36 months.
Review: Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis
Comparison: 1 Active intervention versus placebo
Outcome: 2 Occurrence of at least one serious adverse event over 36 months
Study or subgroup Experimental Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Interferon beta-1a (Avonex) versus placebo
Pakdaman 2007 9/104 7/98 100.0 % 1.23 [ 0.44, 3.45 ]
Subtotal (95% CI) 104 98 100.0 % 1.23 [ 0.44, 3.45 ]
Total events: 9 (Experimental), 7 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
0.01 0.1 1 10 100
Favours experimental Favours control
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Analysis 1.3. Comparison 1 Active intervention versus placebo, Outcome 3 Withdrawing from the study or
discontinuing the drug due to adverse events over 24 months.
Review: Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis
Comparison: 1 Active intervention versus placebo
Outcome: 3 Withdrawing from the study or discontinuing the drug due to adverse events over 24 months
Study or subgroup Experimental Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Interferon beta-1b (Betaseron) versus placebo
BENEFIT 2006 32/292 1/176 12.8 % 21.54 [ 2.92, 159.08 ]
Subtotal (95% CI) 292 176 12.8 % 21.54 [ 2.92, 159.08 ]
Total events: 32 (Experimental), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.01 (P = 0.0026)
2 Interferon beta-1a (Rebif) versus placebo
REFLEX 2012 9/344 6/170 20.9 % 0.73 [ 0.26, 2.10 ]
Subtotal (95% CI) 344 170 20.9 % 0.73 [ 0.26, 2.10 ]
Total events: 9 (Experimental), 6 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
3 Glatiramer acetate versus placebo
PRECISE 2009 14/243 4/238 20.2 % 3.58 [ 1.16, 11.03 ]
Subtotal (95% CI) 243 238 20.2 % 3.58 [ 1.16, 11.03 ]
Total events: 14 (Experimental), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.22 (P = 0.027)
4 Teriflunomide versus placebo
TOPIC 2014 43/423 19/191 25.2 % 1.02 [ 0.58, 1.81 ]
Subtotal (95% CI) 423 191 25.2 % 1.02 [ 0.58, 1.81 ]
Total events: 43 (Experimental), 19 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.93)
5 Cladribine versus placebo
ORACLE 2014 31/410 4/206 20.9 % 4.13 [ 1.44, 11.87 ]
Subtotal (95% CI) 410 206 20.9 % 4.13 [ 1.44, 11.87 ]
Total events: 31 (Experimental), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.63 (P = 0.0084)
Total (95% CI) 1712 981 100.0 % 2.43 [ 0.91, 6.49 ]
Total events: 129 (Experimental), 34 (Control)
Heterogeneity: Tau2 = 0.91; Chi2 = 17.78, df = 4 (P = 0.001); I2 =78%
Test for overall effect: Z = 1.78 (P = 0.076)
Test for subgroup differences: Chi2 = 16.03, df = 4 (P = 0.00), I2 =75%
0.002 0.1 1 10 500
Favours experimental Favours control
76Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.4. Comparison 1 Active intervention versus placebo, Outcome 4 Withdrawing from the study or
discontinuing the drug due to adverse events over 12 months.
Review: Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis
Comparison: 1 Active intervention versus placebo
Outcome: 4 Withdrawing from the study or discontinuing the drug due to adverse events over 12 months
Study or subgroup Experimental Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Interferon beta-1a (Avonex) versus placebo
CHAMPS 2000 1/193 7/190 100.0 % 0.14 [ 0.02, 1.12 ]
Subtotal (95% CI) 193 190 100.0 % 0.14 [ 0.02, 1.12 ]
Total events: 1 (Experimental), 7 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.86 (P = 0.063)
0.01 0.1 1 10 100
Favours experimental Favours control
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Analysis 1.5. Comparison 1 Active intervention versus placebo, Outcome 5 Time to conversion to CDMS
over 24 months.
Review: Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis
Comparison: 1 Active intervention versus placebo
Outcome: 5 Time to conversion to CDMS over 24 months
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Interferon beta-1b (Betaseron) versus placebo
BENEFIT 2006 -0.6931 (0.1676) 12.9 % 0.50 [ 0.36, 0.69 ]
Subtotal (95% CI) 12.9 % 0.50 [ 0.36, 0.69 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.14 (P = 0.000035)
2 Interferon beta-1a (Avonex) versus placebo
CHAMPS 2000 -0.5798 (0.1978) 9.3 % 0.56 [ 0.38, 0.83 ]
Subtotal (95% CI) 9.3 % 0.56 [ 0.38, 0.83 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.93 (P = 0.0034)
3 Interferon beta-1a (Rebif) versus placebo
ETOMS 2001 -0.4308 (0.1876) 10.3 % 0.65 [ 0.45, 0.94 ]
REFLEX 2012 -0.734 (0.2231) 7.3 % 0.48 [ 0.31, 0.74 ]
Subtotal (95% CI) 17.6 % 0.57 [ 0.43, 0.77 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 1.08, df = 1 (P = 0.30); I2 =8%
Test for overall effect: Z = 3.73 (P = 0.00019)
4 Glatiramer acetate versus placebo
PRECISE 2009 -0.5978 (0.1625) 13.7 % 0.55 [ 0.40, 0.76 ]
Subtotal (95% CI) 13.7 % 0.55 [ 0.40, 0.76 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.68 (P = 0.00023)
5 Teriflunomide versus placebo
TOPIC 2014 -0.5621 (0.2069) 8.5 % 0.57 [ 0.38, 0.86 ]
Subtotal (95% CI) 8.5 % 0.57 [ 0.38, 0.86 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.72 (P = 0.0066)
6 Cladribine versus placebo
ORACLE 2014 -0.9676 (0.2136) 8.0 % 0.38 [ 0.25, 0.58 ]
Subtotal (95% CI) 8.0 % 0.38 [ 0.25, 0.58 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.53 (P < 0.00001)
7 Any DMD vs no treatment
0.01 0.1 1 10 100
Favours experimental Favours control
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(. . . Continued)
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
ACISS 2010 -1.0612 (0.299) 4.1 % 0.35 [ 0.19, 0.62 ]
MSBASIS 2016 -0.5447 (0.1183) 25.9 % 0.58 [ 0.46, 0.73 ]
Subtotal (95% CI) 30.0 % 0.48 [ 0.30, 0.78 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 2.58, df = 1 (P = 0.11); I2 =61%
Test for overall effect: Z = 2.95 (P = 0.0032)
Total (95% CI) 100.0 % 0.53 [ 0.47, 0.60 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 6.79, df = 8 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 10.50 (P < 0.00001)
Test for subgroup differences: Chi2 = 3.17, df = 6 (P = 0.79), I2 =0.0%
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 1.6. Comparison 1 Active intervention versus placebo, Outcome 6 Time to conversion to CDMS
over 12 months.
Review: Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis
Comparison: 1 Active intervention versus placebo
Outcome: 6 Time to conversion to CDMS over 12 months
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Immunoglobulins versus placebo
Achiron 2004 -1.0217 (0.4467) 100.0 % 0.36 [ 0.15, 0.86 ]
Subtotal (95% CI) 100.0 % 0.36 [ 0.15, 0.86 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.29 (P = 0.022)
0.01 0.1 1 10 100
Favours experimental Favours control
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Analysis 1.7. Comparison 1 Active intervention versus placebo, Outcome 7 Withdrawing from the study or
discontinuing the drug for any reason over 24 months.
Review: Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis
Comparison: 1 Active intervention versus placebo
Outcome: 7 Withdrawing from the study or discontinuing the drug for any reason over 24 months
Study or subgroup Experimental Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Interferon beta-1b (Betaseron) versus placebo
BENEFIT 2006 78/305 34/182 17.1 % 1.50 [ 0.95, 2.35 ]
Subtotal (95% CI) 305 182 17.1 % 1.50 [ 0.95, 2.35 ]
Total events: 78 (Experimental), 34 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.74 (P = 0.081)
2 Interferon beta-1a (Avonex) versus placebo
CHAMPS 2000 38/193 35/190 16.5 % 1.09 [ 0.65, 1.81 ]
Subtotal (95% CI) 193 190 16.5 % 1.09 [ 0.65, 1.81 ]
Total events: 38 (Experimental), 35 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.32 (P = 0.75)
3 Interferon beta-1a (Rebif) versus placebo
ETOMS 2001 15/154 41/155 14.9 % 0.30 [ 0.16, 0.57 ]
REFLEX 2012 46/346 26/171 16.3 % 0.86 [ 0.51, 1.44 ]
Subtotal (95% CI) 500 326 31.2 % 0.52 [ 0.18, 1.44 ]
Total events: 61 (Experimental), 67 (Control)
Heterogeneity: Tau2 = 0.46; Chi2 = 6.20, df = 1 (P = 0.01); I2 =84%
Test for overall effect: Z = 1.26 (P = 0.21)
4 Teriflunomide versus placebo
TOPIC 2014 108/421 56/197 17.9 % 0.87 [ 0.59, 1.27 ]
Subtotal (95% CI) 421 197 17.9 % 0.87 [ 0.59, 1.27 ]
Total events: 108 (Experimental), 56 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.47)
5 Cladribine versus placebo
ORACLE 2014 119/411 31/206 17.3 % 2.30 [ 1.49, 3.56 ]
Subtotal (95% CI) 411 206 17.3 % 2.30 [ 1.49, 3.56 ]
Total events: 119 (Experimental), 31 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.73 (P = 0.00019)
Total (95% CI) 1830 1101 100.0 % 1.00 [ 0.61, 1.62 ]
0.01 0.1 1 10 100
Favours experimental Favours control
(Continued . . . )
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(. . . Continued)
Study or subgroup Experimental Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 404 (Experimental), 223 (Control)
Heterogeneity: Tau2 = 0.30; Chi2 = 30.84, df = 5 (P = 0.00001); I2 =84%
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Chi2 = 14.76, df = 4 (P = 0.01), I2 =73%
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 1.8. Comparison 1 Active intervention versus placebo, Outcome 8 Withdrawing from the study or
discontinuing the drug for any reason over 12 months.
Review: Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis
Comparison: 1 Active intervention versus placebo
Outcome: 8 Withdrawing from the study or discontinuing the drug for any reason over 12 months
Study or subgroup Experimental Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Immunoglobulins versus placebo
Achiron 2004 4/45 2/46 100.0 % 2.15 [ 0.37, 12.35 ]
Subtotal (95% CI) 45 46 100.0 % 2.15 [ 0.37, 12.35 ]
Total events: 4 (Experimental), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.86 (P = 0.39)
0.01 0.1 1 10 100
Favours experimental Favours control
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Analysis 2.1. Comparison 2 Early versus delayed treatment, Outcome 1 Time to conversion to CDMS at
different follow-up years.
Review: Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis
Comparison: 2 Early versus delayed treatment
Outcome: 1 Time to conversion to CDMS at different follow-up years
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 2-4 years’ follow-up
ACISS 2010 -0.4757 (0.24) 16.9 % 0.62 [ 0.39, 0.99 ]
BENEFIT 2007 (3 years FU) -0.5276 (0.1497) 25.7 % 0.59 [ 0.44, 0.79 ]
GERONIMUS 2013 -1.0217 (0.3537) 10.2 % 0.36 [ 0.18, 0.72 ]
REFLEX 2016 (3 and 5 years FU) -0.5888 (0.1933) 21.1 % 0.55 [ 0.38, 0.81 ]
Tintore 2015 -0.1054 (0.1468) 26.1 % 0.90 [ 0.67, 1.20 ]
Subtotal (95% CI) 100.0 % 0.62 [ 0.48, 0.81 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 8.82, df = 4 (P = 0.07); I2 =55%
Test for overall effect: Z = 3.58 (P = 0.00034)
2 5 years’ follow-up
BENEFIT 2009 (5 years FU) -0.462 (0.1387) 34.5 % 0.63 [ 0.48, 0.83 ]
CHAMPS 2006 (5 years FU) -0.5621 (0.2069) 15.5 % 0.57 [ 0.38, 0.86 ]
PRECISE 2013 (5 years FU) -0.5276 (0.1497) 29.6 % 0.59 [ 0.44, 0.79 ]
REFLEX 2016 (3 and 5 years FU) -0.3813 (0.18) 20.5 % 0.68 [ 0.48, 0.97 ]
Subtotal (95% CI) 100.0 % 0.62 [ 0.53, 0.73 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.58, df = 3 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 5.90 (P < 0.00001)
3 8.7-10 years’ follow-up
BENEFIT 2014 (8.7 years FU) -0.3857 (0.1272) 59.8 % 0.68 [ 0.53, 0.87 ]
CHAMPS 2012 (10 years FU) -0.4943 (0.1552) 40.2 % 0.61 [ 0.45, 0.83 ]
Subtotal (95% CI) 100.0 % 0.65 [ 0.54, 0.79 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.29, df = 1 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 4.36 (P = 0.000013)
Test for subgroup differences: Chi2 = 0.17, df = 2 (P = 0.92), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours early Favours delayed
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A D D I T I O N A L T A B L E S
Table 1. Summary of characteristics of included studies
Type of intervention Route RCTs
N = 10
OLEs
N = 8
Cohort studies
N = 4
Interferon beta-1b sc
(Betaseron®)
sc 1 4 OLEs at a maximum follow-up of 3,
5, 8.7, and 11 years
0
Interferon beta-1a
(Avonex®)
im 2 2 OLEs at a maximum follow-up of 5
and 10 years
0
Interferon beta-1a
(Rebif®)
sc 3 1 OLE at a maximum follow-up of 3
and 5 years
0
Glatiramer acetate sc sc 1 1 OLE at a maximum follow-up of 5
years
0
Cladribine os os 1 0 0
Teriflunomide os os 1 0 0
Immunoglobulins iv iv 1 0 0
disease-modifying drugs - 0 0 follow-up from 2 to 6 years
im: intramuscular; iv: intravenously; OLEs: open-label extension studies; os: oral; RCTs: randomised controlled studies; sc: subcuta-
neous
Table 2. Risk of bias in included cohort studies (ROBINS-I)
ACISS 2010 ACISS 2010
Bias Authors’ judgment Support for judgement
Confounding Serious All known important domains were not appropriately controlled
for
Selection of participants into the study Low All participants who would have been eligible for the target trial
were likely included in the study and for each participant start of
follow up and start of intervention likely coincided
Classification of interventions Low Intervention status was well defined and intervention definition
was based on information collected at the time of intervention
Deviations from intended interventions NI No information was reported on whether there was deviation from
the intended intervention
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Table 2. Risk of bias in included cohort studies (ROBINS-I) (Continued)
Missing data Critical There were critical differences between early, delayed or no treat-
ment in participants with missing data and an appropriate analysis
to address missing data was not done
Measurement of outcomes Serious The outcome measures were subjective and assessed by assessors
aware of the intervention received by study participants. This judg-
ment is applicable to all the three outcomes reported in the article
Selection of the reported result Low There was evidence that reported results corresponded to all in-
tended outcomes and analyses
Overall bias Critical Study judged to be at critical risk of bias in one domain
GERONIMUS 2013 GERONIMUS 2013
Bias Authors’ judgment Support for judgement
Confounding Moderate Confounding expected, all known important confounding do-
mains appropriately measured and controlled for, and reliability
and validity of measurement of important domains were sufficient,
such that we do not expect serious residual confounding
Selection of participants into the study Low All participants who would have been eligible for the target trial
were likely included in the study and for each participant start of
follow up and start of intervention likely coincided
Classification of interventions Serious Intervention status was not well defined
Deviations from intended interventions NI No information was reported on whether there was deviation from
the intended intervention
Missing data Low Data were reasonably complete
Measurement of outcomes Serious CDMS was assessed by assessors aware of the intervention received
by study participants
Selection of the reported result Low There was evidence that reported results corresponded to all in-
tended outcomes and analyses
Overall bias Serious Study judged to be at serious risk of bias in two domains, but not
at critical risk of bias in any domain
MSBASIS 2016 MSBASIS 2016
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Table 2. Risk of bias in included cohort studies (ROBINS-I) (Continued)
Bias Authors’ judgment Support for judgement
Confounding Serious Important domains were not appropriately controlled for
Selection of participants into the study Critical Selection into the study was very strongly related to intervention
and outcome and this could not be adjusted for in analyses
Classification of interventions Serious Intervention status was not well defined
Deviations from intended interventions NI No information was reported on whether there was deviation from
the intended intervention
Missing data NI No information was reported on missing data
Measurement of outcomes Serious The outcome measures were subjective and they were assessed by
assessors aware of the intervention received by study participants.
Follow-up duration not reported
Selection of the reported result Low There was evidence that reported results corresponded to all in-
tended outcomes and analyses
Overall bias Critical Study judged to be at critical risk of bias in one domain
Tintore 2015 Tintore 2015
Bias Authors’ judgment Support for judgement
Confounding Serious Important domains were not appropriately controlled for
Selection of participants into the study Low All participants who would have been eligible for the target trial
were likely included in the study and for each participant start of
follow up and start of intervention likely coincided
Classification of interventions Serious Intervention status was not well defined
Deviations from intended interventions NI No information was reported on whether there was deviation from
the intended intervention
Missing data Serious Reasons for missing data differed substantially across interventions,
and the analysis is unlikely to have removed the risk of bias arising
from the missing data
Measurement of outcomes Serious The outcome measures were subjective and assessed by assessors
aware of the intervention received by study participants. This judg-
ment is applicable to all outcomes reported in the article
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Table 2. Risk of bias in included cohort studies (ROBINS-I) (Continued)
Selection of the reported result Low There was evidence that reported results corresponded to all in-
tended outcomes and analyses
Overall bias Serious Study judged to be at serious risk of bias in four domains, but not
at critical risk of bias in any domain
ROBINS-I is a tool to evaluate Risk Of Bias In Non-randomised Studies - of Interventions (Sterne 2016)
Table 3. Assessment of adverse events monitoring, definition and reporting of serious adverse events
Study Did the researchers actively monitor for
adverse events or did they simply provide
spontaneous reporting of adverse events that
arose?
Did the authors define serious adverse
events according to an accepted interna-
tional classification and report the number
of serious adverse events?
Achiron 2004 No information No information
ACISS 2010 No information No information
BENEFIT 2006 Yes, active monitoring.“Regular visits were
scheduled for safety assessments at months 3,
6, 9, 12, 18, and 24”. (page 1243)
No information
BENEFIT 2007 (3 years FU) No information No information
BENEFIT 2009 (5 years FU) No information No information
BENEFIT 2014 (8.7 years FU) No information No information
BENEFIT 2016 (11 years FU) No information No information
CHAMPS 2000 No active monitoring. “Each center was in-
structed to report all adverse events during the
first six months of treatment, but thereafter to
report only serious adverse events”. (page 899)
No information
CHAMPS 2006 (5 years FU) No information No information
CHAMPS 2012 (10 years FU) No information No information
ETOMS 2001 Yes, active monitoring. “Safety was assessed at
1, 6, 12, 18, 24 months”. (page 1577)
Yes to both questions. “Serious adverse events
were defined according to the guidelines of the
International Conference on Harmonisation”.
(page 1580)
GERONIMUS 2013 No information No information
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Table 3. Assessment of adverse events monitoring, definition and reporting of serious adverse events (Continued)
Motamed 2007 Yes, active monitoring.“Safety assessments
were performed at the end of months 1, 2, 3,
9, 15, and 21 by a neurologist”. (page 345)
No information
MSBASIS 2016 No information No information
ORACLE 2014 Yes, active monitoring. “Adverse events and
laboratory findings were recorded at study
visits and at regularly scheduled interim vis-
its” (page 259). “International Conference on
Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human
Use”. (page 258)
Yes to both questions. “International Confer-
ence on Harmonisation of Technical Require-
ments for Registration of Pharmaceuticals for
Human Use”. (page 258)
Pakdaman 2007 No information No information
PRECISE 2009 Unclear whether the researchers actively mon-
itored for adverse events or they simply pro-
vided spontaneous reporting of adverse events
No information
PRECISE 2013 (5 years FU) Unclear whether the researchers actively mon-
itored for adverse events or they simply pro-
vided spontaneous reporting of adverse events
No information
REFLEX 2012 Yes, active monitoring. “Active monitoring by
personnel was ensured via various testing”.
(page 34). “Adverse events were coded with the
Medical Dictionary for Regulatory Activities
(MedDRA) and analysed according to the pre-
ferred terms”. (page 35)
Yes to both questions.“Adverse events were
coded with the Medical Dictionary for Regu-
latory Activities (MedDRA) and analysed ac-
cording to the preferred terms”. (page 35)
REFLEX 2016 (3 and 5 years FU) Unclear. “Adverse events (adverse events) were
monitored atmonths 25 and 27 and then every
3 months to the study end”. (page 2)
No information
Tintore 2015 No information No information
TOPIC 2014 Unclear. “Adverse events were reported by
study participants or investigators throughout
the study; investigators recorded all such events
on case report forms”. (page 979)
No information
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Table 4. Outcome data from cohort studies
ACISS 2010 Early DMDs treatment (N =
49)
Delayed DMDs treatment (N
= 57)
No treatment
(N = 52)
EDSS score over 24 months’
follow-up
Mean (SD)
Median (range)
Kruskal-Wallis H-Test P value
<0.001
1.2 (0.9)
1.5 (0-3)
1.6 (1.2)
1.5 (0-6)
0.8 (0.8)
1.0 (0-3)
P value versus no treatment 0.016 < 0.001 NA
P value early versus delayed
treatment (Wilcoxon matched
pair test)
0.055 NA NA
Relapses
Mean (SD)
Median (range)
Kruskal-Wallis H-Test P value
< 0.001
0.5 (0.8)
0.0 (0-4)
1.0 (1.1)
1.0 (0-4)
0.2 (0.5)
0.0 (0-3)
P value versus no treatment 0.059 < 0.001 NA
P value early versus delayed
treatment (Wilcoxon matched
pair test)
0.01 NA NA
Tintore 2015
Risk of attaining an EDSS score of 3.0 with early DMDs compared with delayed DMDs treatment
Adjusted hazard ratio: 0.5 (95% CI 0.3 to 0.9)
Unadjusted hazard ratio: 1.1 (95% CI 0.7 to 1.9)
Risk of attaining
with early DMDs
layed DMDs treatment
Adjusted hazard ratio:
3 to 0.9)
Unadjusted hazar
0.7 to 1.9)
DMDs: disease-modifying drugs. EDSS: expanded disability status scale; NA: not applicable; SD: standard deviation
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Table 5. Time until the delayed treatment in open-label extension studies
Study Time until the delayed treatment after randomisation
BENEFIT 2006 Mean (SD): 1.5 (0.73) years
CHAMPS 2000 Median (interquartile range): 30 (24-35) months
PRECISE 2009 Median (range): 29 (0.5 -38) months
REFLEX 2012 Data not reported
Table 6. Safety outcome data from open-label extension studies
Interferon beta-1b Intramuscular inter-
feron beta 1-a (Avonex)
Subcutaneous interferon
beta 1-a (Rebif )
Glatiramer acetate
Participants 487 383 517 481
Serious adverse events -
number of participants
123 65 49 60
Discontinued treatment
for any adverse events
Not reported Not reported 20 71
Discontinued treatment
or were lost to follow-up
for any reason
204 Not reported 146 192
Years of follow-up 8.7 10 5 5
A P P E N D I C E S
Appendix 1. Keywords
clinically isolated syndrome* OR first demyelinating event* OR first demyelinating episode OR first demyelinating attack OR
First event OR first episode OR first clinical episode OR single clinical episodes OR first demyelinating event* OR clinically
isolated syndrome*
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Appendix 2. MEDLINE
((((((((((((((((((((“clinically isolated syndrome*”[Title/Abstract]) OR cis“[Title/Abstract]) OR ”first demyelinating
event*“[Title/Abstract]) OR ”first demyelinating episode“[Title/Abstract]) OR ”first demyelinating attack“[Title/Abstract]) OR
First event[Title/Abstract]) OR ”first episode“[Title/Abstract] OR ”first clinical episode“[Title/Abstract] OR ”single clinical
episodes“[Title/Abstract])))))) OR first demyelinating event*[Text Word]) OR clinically isolated syndrome*[Text Word]))
AND
((((((((((((”Multiple Sclerosis“[Mesh:noexp]) OR (”Multiple Sclerosis/diagnosis“[Mesh:noexp] OR ”Multiple Sclerosis/ther-
apy“[Mesh:noexp]))) OR (”multiple sclerosis“[Title/Abstract]) OR ”optic neuritis“[Title/Abstract]) OR ”optic neuritis“[Title/
Abstract]))) OR ”early multiple sclerosis“[Title/Abstract]) OR ”early stage multiple sclerosis“[Title/Abstract] OR conversion
to multiple sclerosis[Title/Abstract]))) OR early stage multiple sclerosis[Text Word]) OR conversion to multiple sclerosis[Text
Word])
Appendix 3. Embase
#27 #13 AND #26
#26 #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25
#25 multiple AND sclerosis NEAR/5 treatment*
#24 conversion NEAR/5multiple AND sclerosis
#23 conversion NEXT/5 multiple AND sclerosis
#22 multiple AND sclerosis NEAR/5 early AND stage
#21 multiple AND sclerosis NEAR/5 early
#20 ’early stage multiple sclerosis’:ab,ti
#19 ’early multiple sclerosis’:ab,ti
#18 ’optic neuritis’:ab,ti
#17 optic AND ’neuritis’/exp
#16 ’multiple sclerosis’:ab,ti
#15 multiple AND ’sclerosis’/exp
#14 multiple AND ’sclerosis’/mj
#13 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12
#12 single AND clinical AND episode*:ab,ti
#11 ’single clinical episode’:ab,ti
#10 clinically AND isolated AND syndrome NEAR/5 first AND attack
#9 clinically AND isolated AND syndrome NEAR/5 first AND attack*
#8 clinically AND isolated AND syndrome NEAR/5 first AND episode
#7 clinically AND isolated AND syndrome NEAR/5 first AND event*
#6 first AND demylinating AND attack*:ab,ti
#5 first AND demylinating AND episode:ab,ti
#4 first AND demylinating AND event*:ab,ti
#3 clinically AND isolated AND syndrome* NEAR/5 cis
#2 ’clinically isolated syndromes’:ab,ti
#1 ’clinically isolated syndrome’:ab,ti
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
• Objectives. We expanded the research questions including:
◦ is early treatment efficacious and safe compared to placebo or no treatment?;
◦ are there differences in efficacy and safety between the various drugs administered for early treatment?;
◦ is early treatment better than delayed treatment?
• Outcomes. We added ”time to conversion to clinically definite multiple sclerosis“ as a secondary outcome.
• Assessment of risk of bias in included studies. We evaluated risk of bias of the included open-label extension studies using
Cochrane ’Risk of bias’ tool for RCTs (Higgins 2011) and ROBINS-I tool for NRS (Sterne 2016) for the included cohort studies.
• Measures of treatment effect. We used odds ratios to estimate treatment effect in pairwise meta-analyses and network meta-
analyses for included outcomes, and hazard ratios for conversion to clinically definite multiple sclerosis.
• Dealing with missing data. We used Informative Missingness Odds Ratio model to account for the impact of missing outcome
rate (assumed not missing at random) for binary outcomes.
• Summary of findings table. We added the primary outcome ”Withdrawls or drug discontinuation because of adverse events
during 24 months of treatment“ in ’Summary of findings’ table one.
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